Hope this microphone works. Good morning, everyone, and welcome to the city that, just like Praxis, never sleeps. Before I get started, it's Tim's birthday, so I just want you guys to all say happy birthday to Tim. I think we all have very eventful years at Praxis, and I'm sure Tim's is not any different. Going to make some forward-looking statements, and I'm hoping I don't vomit on stage just because I've been getting a little bit of a GI thing, and thanks for Lauren for getting me Tums. Going to talk about more exciting things today than GI, I promise you, although GI is an interesting area. At the end of the day, what I would expect all of us to come out of this is really convinced that we have what it takes to launch these drugs to get to $20 billion or more.
On the other side, that this is going to go and happen again and again. Steve and Megan and John are going to talk a lot about what is next and what is now, so going to be going intertwining between what's we've done, a lot of the things you know, a lot of the discussions we had, but particularly what's next for this phase of the company. Don't consider this a transition. People talk about scaling, like how excited or how afraid you are about commercial. I don't think that's the way we should look into this. Think every single phase in life, as we started with a birthday, brings new joy and new challenge, and this is just one of those, that we're going to be tackling.
I am convinced once we're done with the six hours or so please stick with us, you're going to be as convinced as I am that we are excited, a little bit worried and scared, and I actually think you should be scared if you were not with the giants we have in front of us that we need to conquer to get to the company we believe we deserve to be. But that is totally overcome by the excitement of helping these patients. Most of you heard me saying this throughout the years a number of times. There is one reason only that we are here. A lot of people in this audience, I'm certain, are dealing with something we don't know about, with a condition we don't know about, your loved ones, people you know.
We know people here in the audience who are suffering with early stages of essential tremor, of other conditions. We think about CNS, because of this weird function of our brain, evolution tried to protect it, right. Made it a little harder for us to just go inside and take samples of it and do other things that other fields of medicine. We rely on the incredible people that dedicated their lives to CNS research to really advance the fields. We had incredible developments in CNS throughout the years, many, many years ago. Then we had a little bit of a valley of death where nothing was actually done, and a renaissance, maybe post-renaissance at this point in time, that we are seeing where we can use all those tools.
We will continue to do this for as long as we stand here to help these patients again and again. Keep that again and again at the end there, because you are going to hear today a lot of the motivation. Sometimes that again is going to be like fighting a reimbursement decision. Sometimes that again is going to be standing up when you get a no. But oftentimes it is going to be going to an area that we believe patients deserve for us to go there, just like in the past. I am not the biggest fan of thinking about stock charts or performance as anything but a bunch of things that happen on your day, every single day, and so on, and you get sometimes overly obsessed about it.
I thought, number one, because this is an investor event, and number two, because it is fairly illustrative that you take the journey and look back on the last 18 months, 24 months, three months, six months, you pick it. We just picked a point in time here. Not because of the trajectory of the stock, although I am not going to say I just like it, but particularly because it illustrates two things. Well, many things, but I am going to pick two things and then a few other things in a second. The first one is how I started this conversation, right? We definitely like New York City. There is always a lot of stuff we are trying to achieve. Now, why? The why gets missed. It is because there are people out there or inside this room that need us to do that.
Also have an acknowledgement that you should never start something expecting not to get to the results you planned for. That is actually lunacy. This acceptance of failure that is so often from in biotech and pharma, I think is just a very easy way for cowards to say, "I am not accepting my failures," and we are never going to do that as a company. As much as you accept your successes, you must accept when your assumptions were not there. What allow us to do is to reinforce a number of the principles that are insanely important for Praxis. We can be accused of many things, one of them being incredibly successful, and please accuse us of that.
We cannot be accused of not remain focused, being resilient or anti-fragile, if you want to, the postmodern there, to define the science, follow the actual data and not the opinions, and be convinced of what we are doing there, but also change our minds when new data becomes available, and that is through conviction. Never hiding away from accountability. All right? You are going to continue to do this again and again. I am certain by the end of the day, you are going to be even more convinced that those are certain principles we operate in everything we do, and particularly science, data, commercial, and many other things. Are we a conventional company? God knows. I do not think we have a lot of respect for convention here, and we are very comfortable with that. All of you here know what we have been talking about.
I say we because most of you want to talk about other things with us, right? You all have your personal obsessions, and it varies by the direction of the winds, but it tends to be mostly on the last several months about ulixacaltamide hydrochloride for essential tremor, and then a little bit about relutrigine for SCN2A, and then most recently, EMERALD for DEE, and then a variance of other things. We always try to bring back a little bit the depth of what we were trying to do. Maybe one of the reasons why it was not so clear before is, one, just how large the opportunities are on the top, and then it is just easy to not pay attention to other things, which is totally fine and totally acceptable. Maybe it is because of the perennial questions like, how? How can you advance those things, right?
It is more capital question. Maybe because we are too financially responsible, and when you are looking to analogs, it is hard to match that we are. So birthday boy helped us being there, like really focus on that and with the rest of the executive team, of course. Maybe. We do not know why. But also know that the average of all the opinions is just not to move, so we are not going to be seeking average of opinions. We are going to be seeking biology, market needs, and what these patients really needs. You will hear today that a lot of this stuff we have been doing on the background, we chose to just advance a little bit before telling you all. It is both a products of the company we are today versus the company we were years ago.
In technical terms, the materiality threshold changes, as you all know, and we can actually mature things a little bit more in-house. I think another one is geopolitics, and I think it is important that we mature intellectual property more than ever in the U.S. But others, because we are really trying to make sure that those decisions follow the same process, the same principles we had before. So what we are going to see today is a number of things, and would need a three-day or four-day analyst day or investor day to actually be able to cover in detail everything we are going to be talking here. But as we became more and more convinced and ultimately culminating with the essential tremor successful studies for ulixacaltamide to validate our approach for T-type calcium channel developments, that that is, as you know, is fairly different than other approach that were tried before.
We continue to advance other things on that mechanism, and Steve is going to talk a little bit more of that. It is going to come out in several areas, right? In indications that we believe are adjacent or a little bit far, but there is a little bridge there. It is going to come out as the molecules who are entering the clinic in the next few months, when we have a franchise as large as essential tremor or others indications for T-type calcium channel modulators. I think it is important that we ask not only what do I do with this one drug, but what do I do to help these patients throughout the spectrum they have? We have hypothesis that there are certain properties that might be better modulated by an isoform-specific CaV3.1, or at least a biased 3.1.
We've been advancing that program secretly quite a lot, that's incredibly exciting. You can going on and on here in an entire cluster of genetically defined conditions that we are starting with for our RNA-based approach. It's incredibly exciting. Of course, in general, where we are today, it's more exciting when we sit here about this time next year, right? Those pipeline charts are oftentimes misleading. They give this false precision or false direction on where we are, but to really get in on where we're going to be, I challenge anyone in the audience to match a company that combines the principles, the science, the capital, and the discipline in the way that we've been executing that could move those programs without just like blowing up OPEX, right?
Because I'm sure that on the back of your mind, you're like, "How can this be done with what we have right now in cash?" I can tell you, this is advancing, and you barely notice. Yes, it can and will continue to be done. Another way to look into this, I know one of our ex-presidents, one of the ones that were actually presidents, said this, that if you have a vision, you should reconsider, right? Because this idea of a vision is you think things are going to follow exactly how you plan, and we know full well things never follow exactly as we plan. I'm going to dare to use that a little bit and discuss what could be the minimum that we're going to have in 2035.
2035 is not even 10 years from now, so I cannot do my best JFK impersonation here. In less than two years instead of within the decades, we expect to be even more than we are today, fully integrated CNS company, with many areas of knowledge within CNS being addressed by the programs we have. Does it diminish the importance of the next launch? Absolutely not. Is it enabled, at least in part, by those? Absolutely, yes. Right? Those things are not mutually exclusive. If you look around, there is not a single area here or in the other disease that we're going to be discussing where you can say why. When you fundamentally think on the only entity that matters, that is the patient who needs a treatment, each one of those areas has massive unmet needs.
Some of them self-created by us, right, meaning as society, others really fundamentally without anything. When we're talking about the renaissance in CNS, it's why I dare to say, actually, I think we're post-renaissance right now. Just like AI might bring us back to beauty, I'm a big believer that it's not going to destroy us, but quite the opposite. I think you can see here this bringing back to beauty. This is an investor event, and you're going to be like, "Okay, yada, yada, Marcio, but I've seen more charts like this than you can imagine, and half of them were not true," right? Well, number one, you should know that everything we put in, we thought and we're serious about it. If even part of this happens, what does that mean?
And that is the part I am going to say all of you are missing. There is not a single person in this room, and I believe I know all of you, that accepted the facts of how large these indications are, how good these drugs are, how successful they can be. And just had a serious conversation on the case of the analysts with your compliance department and say, "I just need to actually put real numbers in my model," and starts to take this seriously for what it is. When we are successful to the level we discuss, not base success, because success is always a relative measure, not an absolute one. There is no maximum success. One way to look into this is to look into companies that we are standing on the shoulders of.
A lot of people tend to think, "Wow, you need to be better than, compete with, destroy," if you want to be very fatalistic. We take a different approach. There was a lot of very good work done in CNS, and we are only standing here because of the great academic work that was done, the great scientific work that was done, the great industry work that was done, and great commercial work that was done. But numbers are numbers. And when you look into the numbers you all put it out there for consensus, for those companies that are out here, at the current consensus, we are already on the top. We are already way higher than any write-up in this room ever reflected. So yes, that is a little bit of go back there and look yourself in the mirror when you are writing these models.
That is number one. But when you actually start looking into where it is going to push us, consensus, then things got really, really interesting. Now, does anyone actually need to get there to be incredibly successful? No. But what does that translate? What does that number tell us? That millions of patients suffering are going to be treated with drugs that are effective and that are helping them. What is also telling us is that dozens, maybe more, of companies are going to be created, and I can only wish and pray that they are all better than us, so they keep us better. And that is the cycle of innovation that made this country great, that made people like me and many others here choose to be here to drive the technology, the innovation, and the success of the United States.
So it is not only a reflection about us, it is a reflection about what can be in the industry when we are successful. But what is it there? Like, what do you have to believe? So we already believe in 10, so you cannot pedal back, cannot go back and decide that that is no longer. We are asking you to believe that maybe some of the assumptions must be refined, and it is not by a lot. Then you look into the gap, which I am certain we are going to close at least partially today. And it is a lot bigger than what you are even talking about. Now, none of them includes things that were in the original charts. Now, don't believe me yet. Listen to the rest of the conversations that you are going to be having today.
Listen to the science, to the operations, but particularly ignore your system one. What feels like in many conversations I have with all of you, is that just like any other humans, we're looking for a pattern. You're asking yourselves, as we all ask ourselves, "What are the last three, 10 launches in CNS that got to this place?" We talk a good talk about first principles, but you do a really poor job on applying first principles. Ask a slightly different question or set of questions. What are the conditions here? Are those conditions the same? Name one indication with millions of Americans without a treatment. Now, add on top of that, effective drugs. Add on top of that, physicians willing and able and interested.
Then you put on the other side, add a company that is as committed to smaller indications as it is to big indications, as is the case for us, as you all know. Then it becomes actually pretty simple to get to this. I'm not trying to convince you to subscribe to any of those numbers. I actually don't need to. Because no matter how skeptical you are, and I don't believe many of you are, you are absolutely all very mathematically inclined, so you know math pretty well, so that part should be easy. Pick your number, pick your factor, divide by three, divide by four, divide by five. If it's going to make you feel comfortable, please do it. But don't ignore the other principles. Don't ignore the patients out there. Don't ignore the lack of good therapies.
As you're going to hear, as we progress with the day from people far more capable, smarter, and prepared than I am right now, there is a lot of work that goes behind each one of those numbers. We're going to talk about the unmet needs. We're going to talk about what we know. Always try to be very true to what we hear back from physicians, healthcare systems, payers. Going to have a little unusual panel today, as I want to thank the moderators for agreeing to do that. It's really unbiased panels with world experts on movement disorders and epilepsy. They're going to be talking to you and answering your questions about what they think is going to happen on this treatment.
Then you're going to hear a fair bit about how we're going to make this to a minimum on what we just put in front of you. While I can't promise that I'm just going to disappear, I'm going to come back here a few times just to give a couple remarks. I definitely am going to try to take a step back now so you can hear from my amazing team. I'm going to finish this first part with this. This was not easy, right? It's never easy to develop drugs. But it was easy to row against the currents with a small group of people. If you examine history, large groups of people could never accomplish real big things, because the bias take over. I was just talking about system one and system two, and for the literate of you know what I'm talking about.
For the illiterate of you, become literates. Nana Palm is shaking his head. He is like, "Marcio." It is very important that you remove some of the bias today. That is my only ask, is that you observe for what it is versus for what you believe to be. With that in mind, I am going to get Megan to talk a little bit about how we are going to do that. Thank you so much.
Thanks, Marcio. Good morning. I am Megan Sniecinski, our Chief Operating Officer. Actually, this month I will hit my five-year anniversary with Praxis, which brings me to just over 10 years working side by side with Marcio, building and launching in the biotech space. In my time here, I have had the privilege of leading the Essential3 study execution team. After I left Merck, I moved into the rare biotech space. So it is extremely special to be standing here just 10, 11 weeks away from the PDUFA date for Ulixa to bring forward yet an innovative treatment for such a large indication with equal unmet need. I also started my career on the manufacturing floor. So the 23-year-old me, as a chemical engineer, kind of can't believe that I am standing here today setting commercial demand forecasts requiring metric tons of API for Ulixa and filling factories.
It really feels like an amazing moment. It is really exciting to be on such a cusp of an inflection point for this organization and to be in a unique position to have two firsts. When we read out the data in the fourth quarter of last year for these programs, while we set our sights on preparing for two simultaneous launches, we made that deliberate decision and commitment to actually build for this growing portfolio Marcio just laid out. We didn't build for two, we built for the many. Today, I am joined by Erik Johnson, our Head of Commercial, and John Bullock, his Head of Sales, and we are really looking forward to taking you through how we are setting up Praxis to realize the vision Marcio just laid out. First, we built this through first principles, as Marcio mentioned, and our signature disciplined approach.
We invested with conviction, so we built the capabilities upfront. We built exceptional teams with individuals who share the same mindset and standard of excellence each of our leaders holds today. We also customized the experience for both markets to bring forward the solutions so that patients and the physicians can focus on the outcomes and what matters for their patients. Lastly, we enabled real-time data and analytics so that we can monitor and drive this launch execution. We built all of this to repeat, building it for both a rare pediatric epilepsy as well as a large indication with millions of people suffering today. Let me first start with how we thought about the investment. Many launches are built incrementally. They start out with a small team, and then they build people or capabilities or systems as the demand shows up.
But that means they're always chasing the launch curve. We deliberately chose to invest upfront and ahead of launch and plan for the success case. That investment went into three core areas. First, we have field forces in place ahead of launch with extra capacity to respond to that dynamic targeting and demand we anticipate. We also have an innovative integrated hub and distribution network and a cutting-edge Commercial Data Foundation. Compared to some of the recent successful first launches, we expect to invest over and beyond, even adjusting for the fact that we have both a rare launch and a large indication launch happening simultaneously. This is all deliberate. We have the balance sheet to do it, and waiting for certainty before deploying it would just be too late.
This approach, in our view, helps us accelerate the patient impact we want to have and maximize the long-term value of this portfolio. In building our field force, as I mentioned, they're fully dedicated to relutrigine and ulixacaltamide, and in place ahead of launch. The approach we took was disciplined. We sequenced the hiring so that leaders brought in their next level and recruited their teams in place. We targeted individuals with strong track records of performance, the President's Club winners, the top performers, and individuals that have had multiple U.S. launch experience. Secondly, our onboarding of these teams. It mirrored how we work, intense and in-depth, to give all of our new hires a deeper appreciation of our values, our way of working, and the markets that they're going to be launching in.
From a training perspective, we shifted away from the classic traditional module and test, and are really embracing AI to help prepare our team. Our reps practice in AI simulations. They have to teach back the material to their team members in pods, and then they're certified through a full simulation. In our view, this helps them master the content they need to understand before they hit the ground and help present and perform better in front of the customers. John also brought us a tailor-made engagement model that we're deploying across the full customer-facing organization so that any customer that may interact with Praxis experiences us the same way. We believe it's going to be fundamental to helping them act and change their treatment paradigm faster than normal and traditional models. I know John's going to speak more about that later today.
We also believe quality of the experience, not the quantity of the prescriptions, is what's going to win for us in the long run for both Ulixa and relutrigine. This is our core launch priority, and the idea is straightforward. Some launches start out slow and gradually build. Others may chase volume early on, and that may create short-term fast start, but a ceiling is lower. We're aiming for the largest area under the curve, which means getting the first experience right for every patient and every physician. That's what we feel will build the physician's confidence and keep the patients on therapy long- term. This matters in essential tremor because no neurologist has just one patient. They have tens, some may even have hundreds. So how their experience goes with their first patient shapes their future prescribing activity.
For relutrigine, this experience will be a total treatment paradigm shift for the 2A and 8A community. These physicians and families have never had a product developed specifically for them and approved in their DEE. Powering our commercialization is our Commercial Data Foundation. We are obsessed about data and analytics at Praxis. It is what has driven our discovery. It is what has helped us recruit trials and execute with speed. Now we are moving that same obsession into the commercial phase. We have built a leading-edge data and analytics foundation that unifies the patient, the provider, the HCO, and the payer data in one unified view that we can use across the full business. We have moved beyond the disparate systems companies traditionally have, the static dashboards, the lagging data, and have integrated more than 30 different data inputs into our commercial data warehouse.
This shared infrastructure will support both launches and enable many of the different data uses across our business that you see here on the left. In the past, launches have suffered from lagging data, which means they are learning things too late. Our system is built so that we can automate the workflow, activate the actions, monitor in real time how we are performing, and ultimately give us the visibility we need every single day in how the prescription and the patient journey is progressing. Lastly, our unique position gave us the competitive advantage to architect and activate what we view as a Hub of the Future. The scale of ulixacaltamide allowed us to actually set this standard, and now our entire portfolio gets to benefit from it.
We are fully integrating the end-to-end flow across the hub and the distribution, from prescription writing to the patient services, and then ultimately to the specialty pharmacy. In our view, the traditional outsourced hub model could not deliver the speed, the personalization, or the efficiency we demanded. We also think this model will deliver the best patient and provider experience. They will see one branded Praxis front door, have one support experience, and each patient would be routed to the SP aligned to enable more seamless access. In our view, this single coordinated pathway ensures the right patient with the right coverage gets to the right SP most likely to clear that PA, dispense successfully, all with minimum physician effort and faster speeds to therapy. We will have the data integrated end-to-end, so we will have a clear view of that prescription and patient journey every single day.
We also feel this model removes a lot of the barriers and friction patients and providers have felt traditionally with other launches, and it also fully aligns the incentives through the chain when you think of us using payer-owned SPs and our ability to intelligently direct the prescriptions. Erik will actually walk through this in more details, both for how we have tailored the model to support ulixacaltamide and relutrigine and each of their specific market needs. We are ready for both launches, and both are first of their kind. We are definitely excited to be here today to share more about how our commercial strategies are supporting these two brands and driving that $20 billion vision that Marcio laid out this morning. I will start first with ulixacaltamide and essential tremor. It is a CNS disorder that has been completely neglected for decades, and where ulixacaltamide is about ready to change that.
We are really hard-pressed to think of another program in late-stage development with this kind of blockbuster potential, a market so large and so underserved. In our view, we are awakening a sleeping giant in neurology. There are nearly 9 million patients carrying the high burden of this disorder every single day. They experience significant functional disability. They struggle to write their names. They struggle to eat a bowl of soup. They struggle to brush their teeth or even pour a glass of water. The impact goes beyond essential tremor. They experience devastating daily losses that progresses and worsens with time. Lastly, the impact goes beyond just that tremor. These patients feel embarrassed, develop anxiety, depression, and essentially social isolation. It is all because today the treatment options are just limited. There is minimal efficacy, lots of contraindications, and simply tolerability trade-offs.
We know that essential tremor really limits the full range of daily activities most of us do every day. In our recent survey of nearly 1,300 patients, they have confirmed what we have heard for years. Essential tremor is a devastating disease that impacts them every day. We have been carrying the prevalence of 7 million, which actually comes from 2012 data. What is interesting about essential tremor is it becomes more common with age. So an aging population grows essential tremor market faster. Holding the 2012 age-specific rates and adjusting for population growth, we are actually sitting here today with 9 million patients in the U.S. This will grow to 11 million in 2040, which represents more than 10 x the size of Parkinson's. Of the roughly 9 million, about 2 million today are actively managed, and that is the population we see addressable at launch.
It is no wonder why 2 million are only seeking treatment and actively managed. No good options exist today. Many people are just told it simply runs in the family, or if nothing works for your mom or dad or aunt or uncle, why am I going to seek treatment? Unfortunately, patients just simply learn to cope by adjusting their life, and this is what is about to change. What we have been saying is, if this number does not more than triple in the next decade, we have not done our job. We also asked physicians how they see this. Back in March, we ran a large observational study to gather their views on the unmet need, the current treatment discussions, and how they see the Ulixa data impacting their future clinical decision-making.
We had more than 2,000 physicians in the U.S. respond. A really unique feature of this study is that we required respondents to submit their NPI, which allowed us to match back to claims. Not only did we hear their perspectives, it collectively represents a population of over 40,000 essential tremor patients under their care. This gives us a wealth of perspective and reinforces our understanding of the market landscape going into launch. Erik will go through in more depth what we heard through this survey, but overall, it echoes what we have been hearing from patients and reinforces how the current care just simply falls short. We are humbled to be here today with the first drug under FDA review for essential tremor in over 40 years.
With that, let me turn it over to Steven, who is going to take you through the exciting and compelling data that served as the basis of our NDA. Megan.
Thank you, Megan. For those of you that do not know, I am Steven Petrou. I am one of the co-founders of Praxis and currently serving as the President of Research and Development. I have had the good fortune to be involved with Praxis since the launch, since the very, very start in 2015 when it was a couple of people in a room in Cambridge, Massachusetts. I have also been very lucky to be at the birth of every single asset that is in Praxis, been involved in one way or another. I am excited to be here today when we reach this incredible point in the journey of the company.
I mean, it is over 10 years for me that I have been a part of it, and a much more active part in the last five years when I left my role as a director of Australia's largest research institute, the Neuroscience Research Institute, to take on the role here at Praxis. It has been an incredible journey and a very fulfilling one, compared to writing papers and grants in particular. As Megan said, Essential3 is one of our flagships. It is the first positive phase III program in essential tremor. With ulixacaltamide, it is a selective T-type calcium channel blocker that acts on the cerebellothalamocortical circuit that drives tremor. It makes it the first mechanism-based approach to this disease, and that is a great milestone. The program was built to answer two questions: Does it work? And does the benefit last?
It was also the first fully decentralized phase III program in the U.S., with participants in all 50 states, and incorporated a unique design feature where study and treatment arm allocations were fully blinded to study staff, investigators, and participants. You will see how that gave us a lot of flexibility in the analysis of this trial to look at it in various different ways and to really understand about reproducibility and signal. We do firmly believe that E3 sets a new standard for clinical trial methodology in neurology. ET's impact is broad, pervasive functional problem, not a single task or a trivial one, which is why an endpoint like activities of daily living is the right way to measure benefit. There has been a lot of churn about the way to measure benefit in essential tremor.
This is the baseline disability for our 698 trial participants, which mirrors what is seen in clinical practice. The mean baseline TETRAS-ADL score is 31 out of a possible 48 of our participants. As shown here, participants experience significant disability across nearly every daily activity, not just one or two tasks. Close to nine in 10 score in the top two bands for pouring, carrying, feeding, and drinking, and it progresses with time. These patients have lived with ET for 30 years on average, and 94% worsened in just the past three years. The trajectory is not great for these patients. I am sorry, my computer decided to glitch. Oops. Sorry. The unmet need is high, which is why we are thrilled Essential3 is the first successful phase III program for any drug in essential tremor.
In 40-plus years of trying to treat this disease, no one has done this, and we have done it with ulixacaltamide. Both studies were positive, with clinically and statistically significant results across primary and secondary endpoints. These results show strength in five dimensions, and I will take them in turn: rapid onset, maintenance of effect, deep response, consistency, and robustness. First, we will look at rapid onset. Day 14 was the first time we assessed patients, and that falls within titration, yet patients had already gained roughly five points on the TETRAS-ADL. What I find most compelling is that these curves come from two independent studies. You can see here study one and study two, and that was the advantage of the blinding of the allocation, not just to the arm, but also to the study.
Study one treatment arm and the study two lead in here shown potentially overlapping one another. That reproducibility tells us that the effect is real. Physicians have acknowledged in our advisory boards, as well as the observational study that Megan referred to, about how compelling this feature is, especially when thinking about the conversation they will be having with their patients. The benefit holds as the bar rises. Here we look at the share of study one patients having 1x, 2x,3x the minimum clinically important difference of 1.25 points on the mADL at day 56 and day 84. At every threshold and at both time points, more patients on ulixacaltamide reached that bar than patients on placebo. The effect is not driven by marginal responders. The benefit fades when patients switch to placebo.
In study two, patients who stayed on ulixacaltamide kept their gains, while patients that switched to placebo lost them, and we see this on the mADL and on both clinician and patient global measures. Benefit that fades when the drug is withdrawn is strong evidence that the benefit came from the drug. Long-term follow-up. This is new, and it is new in a way that I want to be very clear about the result, because it addresses an important aspect about the study. Study three is our long-term safety study. It was built to collect safety, not efficacy. For the patients who rolled over from study one and study two and have now been on drug for well over a year, we had no formal measure of how they were doing.
A number of you in this room asked us for exactly that, so we amended the protocol and the TETRAS-ADL assessment into study three. Collection for that began this month. 68 participants have been assessed so far, and it is continuing across the full active cohort. What I am showing you is a first snapshot, not a finished data set. Here that is. Patients remained in the program for an average of 95 weeks, nearly two years. In this entire cohort, at week 12, the mean improvement from baseline was three points. At week 95, it is six points. This is a remarkable result. Think about what should have happened instead. Essential tremor is a progressive disease, and as I mentioned earlier, 94 of these patients told us that their disease got worse over the three years before they entered the study.
The expected trajectory for this group is further decline. Clearly, that did not happen. Instead, the effect is extremely durable. Perhaps we should have expected durability, given that so many of the participants remained for so long in the extension study. Finally, bear in mind, even on propranolol, the pattern most neurologists in this field know is that the response fades with time. The response is deep. 60% improved by at least two points on the TETRAS-ADL. Nearly half have regained four points, and about one in five patients improved by 12 points or more. That is the equivalent of improving by one full level in each of the 12 daily activities. The difference versus placebo is statistically significant at every threshold. These kinds of functional benefits are remarkable. The consistency continues. We see consistent results across studies, subgroups, and endpoints.
The benefit is significant in every subgroup we looked at: age, sex, family history, intention tremor, and whether or not patients were taking propranolol or other ET medicines. This is particularly important for new treatment patients, regardless of baseline demographics. We could not find any predictor of response, so physicians can reasonably discuss ulixacaltamide with all of their patients. We also see an additive benefit on top of propranolol and ET medicines in general. From a prescriber's perspective, they can simply add on ulixacaltamide. Global impressions rated by patients and by clinicians both favor ulixacaltamide at day 56 in both studies. These measures capture something different from the ADL score, which makes their agreement meaningful. This is the kind of consistency that builds physician confidence and is why we are seeing strong interest and engagement from the medical community.
Let me finish on robustness, because if I was sitting where you are, this is the slide I would really want to see. We have shown you sensitivity analyses before. These are different. These are the actual analyses the FDA asked for. What is on this slide is not simply our account of how solid the result is. It is a window into how the agency itself was thinking about whether the primary endpoint would hold. One thing before the numbers. Every analysis here is run on the ITT population. That is, everyone randomized, including patients who contributed no data at all. That is the most conservative population available to us, and it is the toughest test you can set for a dataset. The left panel is a four-model-based analysis. The primary model gives a treatment difference of 2.57 points on the ADL scale.
Multiple imputation under missing at random, 2.59. Placebo-based imputation, where we assume every missing patient on drug behaved like a patient on placebo, 2.12. Baseline observation carried forward, which assumes every missing patient reverted all the way to where they started with no benefit at all, 1.41. P equals 0.0019. Four analyses out of four, every one significant, including two built to be deliberately punitive. Now to the tipping point on the right. Here we apply an explicit penalty to the missing patients on ulixacaltamide and ask the question, how large must that be before the result breaks? At 2.5 points, still highly significant. At 4.5 points, still significant. It takes a penalty of five points before significance is lost.
If you hold that number against the treatment effect, which is 2.57, the penalty required to break this result is roughly twice the size of the benefit. So for the primary endpoint to be wrong, every patient on drug would have had to worsened about twice the whole treatment effect. That is just not a plausible picture. Some of you will notice that this is a stronger statement than you have heard from us before. That is because we have previously walked through a range of different sensitivity approaches, mostly in response to conversations with many of you in this room. What we are showing is the definitive set on the hardest population. So ulixacaltamide delivers a compelling efficacy profile, impactful for both patients and treaters. The neurologists and key opinion leaders we have engaged confirm the evidence is strong and meaningful. The wait is over for an effective oral therapy.
This is the evidence behind the first medicine designed for essential tremor, with a PDUFA date of January 29, 2027. With that, I will hand over to Erik Johnson, our Head of Commercial, to talk about how we launch it. Erik.
All right. Thank you, Steve. Good morning, everybody. Very happy to be here on the back of how exciting the data is and everything that has been set up to this point to talk a little bit about how we are going to commercialize ulixacaltamide in essential tremor, and then be back up a little bit later to talk about relutrigine and DEE. First, a quick introduction as I move to my slide here. So I have 25 years in the biopharma space, 20 of those at Bristol Myers Squibb with a mix of strategy, marketing, commercial, and sales. Then I had stints in the U.S. leading brands, worldwide franchise management, had the opportunity to launch multiple blockbusters. Since I left BMS in 2021, I have been in the biotech startup space.
The highlight for me over that time is the privilege to launch truly groundbreaking therapies to patients that desperately need them and to drive innovation in how we do that. Being here now at Praxis, cutting-edge science, innovation is everywhere. It is the culture and who we are as a company. It is truly unprecedented for us to be launching two products back-to-back, right on top of each other. You will learn a little bit more this afternoon, but a robust pipeline behind that poised to deliver even more. To say that I am excited to be a part of the journey would be a huge understatement. All right, turning to essential tremor and ulixacaltamide here, this is a commercial leader's dream. It truly is awakening a sleeping giant as we think about essential tremor.
As you heard from Megan, it is a large market of about 9 million patients, but only 2 million of those patients are actively seeking treatment due to the lack of innovation over the last 40 years. While the majority of patients are treated by neurologists and movement disorder specialists, there is a meaningful number that are treated by neuro-like primary care physicians. We will be launching with a parallel line specialty pharmacy distribution network, and considering the market factors I just described here, three keys to success for us. One is direct-to-patient activation through our DTC campaigns. I will talk a little bit more about what that looks like, both from a disease state education perspective and then once we launch. Ensuring flawless first experience for both physicians and patients right out of the gate.
A program focused specifically around titration for the patients initiating therapy and then transitioning into maintenance therapy. Reinforcing our philosophy of quality over quantity. Megan talked about the importance of quality in that first experience, and you will see that through our launch plans. Megan talked to this study a little bit earlier on about 2,300 physicians that we surveyed within essential tremor. 90% agree that regaining even one function, like brushing teeth or pouring coffee, is meaningful. 92% agree that maintaining function over time is clinically meaningful, and 85% are comfortable counseling on titration. In the neuro space, multiple products have titration. This is not something new to our target audience once we launch ulixacaltamide. From that same survey, 90% of HCPs treat before the symptoms become highly disruptive to their patients.
88%, encouragingly here, rated the overall ulixacaltamide profile as favorable, and 36% said that they would likely to prescribe ulixacaltamide to 36% of their patients. That is a mean number coming from the survey. The Essential to Me disease state education campaign is live now. It is in the market. We are targeting and focused both on HCPs and on patients. From an HCP perspective, we want them to see ET as a serious disease warranting active treatment, to value daily living function over just tremor amplitude, and to see this mechanism as distinct from the nonspecific options they have, like propranolol. For patients, we want to introduce Praxis as an authority in this space, and for them to feel that their lived experience is reason enough to seek care.
We also reinforce the correct diagnosis code, as this will be important for us out of the gate from an access perspective. Anecdotally, since this campaign has been in the market, we are hearing from physicians that patients are coming in and asking about ulixacaltamide. Thinking more broadly about the DTC campaigns and when we begin to launch ulixacaltamide, this is already validated. This is exactly what we used for patient recruitment in the E3 program that Steve just covered. This DSE campaign, as we look at the disease state portion in market today, is performing better than what we saw in E3 when we think about conversions and cost per conversion to bring patients in. At launch, we will shift to a DTC campaign focused on branded content to drive awareness with patients and encourage undertreated and discontinued patients to seek care with their physicians.
This is focused on the 2 million number that Megan talked about before that are currently seeking treatment. Longer- term, we will look to get into that broader market and expand beyond the 2 million patients and capture more of the 9 million fully diagnosed. Our Dare for More goal, I think, would be capturing 5 or 6 million more patients in that space. Neurologists responded enthusiastically to the profile of ulixacaltamide with explicit excitement around the rapid onset of effect, once-daily dosing, and use alongside their current ET therapies. Our support begins before the first patient is prescribed or starts therapy. We will have a Praxis conversation with every physician out of the gate.
You will hear a little bit more from John in his section, but we have also built in capacity with the field team to be able to reach a physician within 24 hours of writing their first script. Getting into the Praxis Horizons and our hub again, Megan covered this from a high level in her section, but we really are combining three things in a launch that most other brands keep separate, as we think about the prescription writing, the patient services, and our specialty pharmacy network. The hub is designed to remove barriers before physicians, their office staff, or patients experience them.
With our Commercial Data Foundation giving us near real-time information and data on what is going on across the entire patient journey, we not only are able to address any barriers that come up in real time, but we are able to anticipate and learn from those so that we are proactively removing friction in the system as we move forward. This allows us to start with a competitive advantage, but that is the baseline, and we are going to improve from there. At a high level, the HCP will submit an ERX through their EHR, comes into our digital pharmacy. The pharmacy will verify benefits same day. They will outreach to the patient same day via text, and then they will route to the correct in-network specialty pharmacy. The digital pharmacy keeps the patient informed every step of the way. They will know exactly what is going on with their scripts, into titration, into the maintenance portion.
We have a hands-on approach then to supporting patients from a titration perspective and moving them into maintenance therapy. The principle is own the experience. If a physician's first prescription is smooth, they will prescribe again, moving quickly from trial to adoption. Quickly here, we invested early in manufacturing, supply, and distribution, so we have plenty of product available at approval. Our specialty pharmacy does cover the vast majority of Medicare Part D patients. Marcio has communicated previously our planning pricing corridor here is $50,000-$100,000 per year. This is a planning range. Final price will be set at launch. The chart here shows gross annual prices for selected analogs from about $52,000 for Rezdiffra, up to about $110,000 for AUSTEDO.
You can see the patient population here ranging from about 1 million to 9 million, all of these within the neuro space, so the right analogs to be looking at. As we think about what we see in the market, there is going to be three principles that will guide our pricing strategy. One, price responsibly to capture the value without restricting access for patients. Two, benchmark to in-market analogs. Three, reflect the first in class and clinical value that we bring to the market. Just taking an illustrative example then, if we anchor to those patients that are currently seeking treatment, the 2 million number we have talked about a number of times, and just look at 1% penetration into the market times a $50,000 net price itself equals $1 billion.
That $50,000 net price would be a $70,000-$80,000 WAC with about 30%-40% gross to net built in to get to these numbers. This is not guidance. It just simply shows that every point of market share that we are able to achieve generates blockbuster sales in and of itself. What gives us confidence that we can drive share then in this market? Ulixa would be the first ET-specific therapy, as you have heard. Today's standard of care is ineffective, poorly tolerated. There are no near-term competitors in clinical development. Our DTC encourages patients to start the conversation. We are already seeing some progress there. We are deploying a full sales force from day one. We will not be chasing numbers and building as we launch.
On the right, we are using the same math that I just showed on the previous slide, so the 1% equaling $1 billion, 10% at $10 billion, and 36% at $36 billion. The 10% number represents the average analyst estimate of market share for this population. The 36% comes from the survey we have covered earlier on the stated intent. That is stated intent, so we take this as the upper bound of enthusiasm that we might see from the market. This is just based off of the 2 million number. I talked about our Dare for More goal as we look to expand beyond that 2 million number and capture more of the 9 million patients within the essential tremor space. It is not hard to get excited about even a little bit of market share in that untreated population can drive serious numbers and serious excitement around Ulixa.
And with that, I'll turn it over to John to take you a little bit through where we are from a field perspective.
It's a lead in $36 billion to bring the sales guy up, right? Very fitting. I am John Bullock. I've been leading sales organizations with 26 years of progressive experience at USA Today, Amgen, Pfizer, and Alnylam. I've had the opportunity since 2017 to lead some launches, some of them blockbuster, and have had incredible opportunities to build amazing teams. But there could not be a more exciting opportunity than what I'm going to share with you this morning, and I'll start with ulixacaltamide. So, how do we build our approach with the targeting, which is critical to any launch? The first step that we did in leveraging Komodo and IQVIA data was identifying where the essential tremor patients are at currently. Then you map those patients back to the physician, and then we rank, right?
And you all are very familiar with the tiering by physician based on their diagnosis and treatment focus. After that, then we identify which of the areas that you have, and it's clear here, you have academic neurologists, you have community neurologists, you have advanced practice providers, geriatrics, primary care, which is an interesting segment, and any other specialties. What that helped to inform was the building of our team, which is a 300 field sales team. So we're investing in a team that is built for the launch and sustained for the future. You have a focus on 19,000 total targets, right, that are part of that universe, 13,000- 15,000 neurologists, and you have that 4,500 - 5,500 group of PCPs, which is important. I think the most important thing on this slide is that we have already built in dynamic targeting capacity.
What that essentially means is, if you have someone that attempts to prescribe the medication that we have not called on, they automatically get dialed in, and within 24- 48 hours, we are making contact with that HCP. You're thinking about that titration journey, right? If you fast-forward to that, this ensures that the office is educated, that they can then pass that knowledge and education to the patient as to what they need to expect with the onset of the drug. So, that really is important, and we were planning for that here at the beginning. Then when you think about the activities that we'll have prior to approval, let's really focus on these three key areas. The first is disease state education.
This is a market that has been dormant for several decades in terms of providing education to HCPs, so we're going to do that in pre-approval. We want to deeply understand the dynamics that are taking place within the office, right? How does that office run? What are the times that we can see them? And making sure we're building those relationships prior to approval. You have this last important piece of understanding what is their RX workflow? What are they doing currently today? Who is handling the prior authorizations in the office? What is the burden of the office? We want to understand that intimately. We're going to move at approval to then going and educating on the therapy, on label, of course, and then leveraging our best-in-class HCP engagement model. Megan talked about this earlier.
I just want to highlight the fact that this model is a common language that's leveraged across the cross-functional team for our customers. It is also built on creating dissatisfaction with the current state of the market, right, and what they have to treat, and then moving them quickly to taking an RX action on behalf of that patient. Also, the training, right, Megan talked about this as well, it is incredibly rigorous. We're leveraging AI simulations that actually measure how many times someone says "ah" and "um" as a part of their scoring system to move them on. We expect our sales organization to be able to communicate very, very clearly and articulate our messages very, very clearly. So we're taking them through their paces in world-class training. We want to make sure that there is a readiness level for the patient dialogue, right?
We want to make sure those HCPs within the offices are very, very comfortable with having the conversation to talk about the rapid onset, right, of the drug. And then obviously, and this is really important for fulfillment of the script, that there's awareness of Praxis Horizons. Erik walked us through some of that. There's a digitally integrated pathway to take the burden off of the physicians' offices, right, and off of their staff to make sure everything from the prior authorization all the way, including appeals process, is addressed. So I talked about titration just for a moment, and if you think about the high touch that's needed, we'll walk through this. There's first an initial welcome by a pharmacist that will cover off on the disease, the product, and the expected side effects, right? So that'll happen, really at day one.
Through early titration, there'll be a nurse and pharmacist reach out for check-ins on everything from AEs to missed doses as a result, and also interacting with the caregivers if needed, which is important. We'll focus on the dose progression, confirm that the patient is ready to take the next step, which is very, very important, and also talk about the tolerance as well. And then maintenance, right? Coordinating to getting them to 60 mg, making sure that we have someone that's working with them, and then finally, persistence, right? This is our push towards persistence and making sure that they're able to stay on drug. So the takeaway here is, there is a very broad cross-functional team that will be supporting throughout this entire process.
Where there is the higher likelihood of discontinuation, we are going to drop that for about that third of patients that may need that additional support. If you think about the coverage landscape, which we are very, very comfortable with, it is an anticipated mix of 65% Medicare Part D and 30% commercial. The rest will be made up of Medicaid and government programs. At launch, the Part D formulary exception request will be available, right? That happens right at the very beginning. With approval pending, depending on clinical justification, right? As we have talked about, these are patients suffering with disease for decades, have probably met some of those criteria, prior use of propranolol, when the PA criteria is set. That takes place about three to six months into the launch, right?
Many of the policies that will be put in place, the patients would have already qualified. We are very, very confident in that. Even on the propranolol use, if you think about it, many have tried, but there are also many that are contraindicated for the drug itself, right? That will also provide that immediate access to the medication. The last point I want to make is really, really important. I have had the opportunity to launch some amazing products. This is the first time that I have been a part of an organization that has had an asset that has a large and growing market, a therapy where patients need it and physicians are ready to prescribe, and the people, systems, and intense focus is there to over-deliver.
One of the things that we do, and this is through our agile model, is make sure it is all done through collaboration, and we do not operate in silos. We do that internally, but we are certainly going to do that externally. We will not operate in silos. We are going to partner with the HCP community in delivering this amazing medication. It is with that, and speaking about our HCPs, I have the pleasure of bringing up two experts right now. I would like to welcome up Dr. Daniel Kremens, Professor of Neurology and Co-Director of the Movement Disorder Program at Thomas Jefferson, and Dr. Bill Ondo, Professor of Neurology at the Weill Cornell Medical College, Director of the Movement Disorder Clinic at Houston Methodist Neurological Institute. We are also going to welcome up François Brisebois with LifeSci Capital, who will moderate this session. Gentlemen, welcome up.
I have the beard.
Mics are good, yeah? It's funny seeing that picture. It's amazing how that's not that old, and that's what happened when you have young kids. They took all my hair, is what happened in one year here, actually. Great to be here. Thank you very much, everyone, for being present. Thank you, Dr. Kremens and Ondo, for doing this. I just want to be very, very clear. This is not scripted at all, so I look forward to hearing these answers just as much as you guys do. The questions we're going to go through, a lot of these are questions that come from investors, and we'll just kind of go through a theme. With that, I think before we go into it, maybe a little more background on yourselves, on how many patients you see, maybe annually in your practice, and your relationship to ET.
I have been a movement disorder specialist. I did a fellowship at the University of Pennsylvania in movement disorder, and I see hundreds of patients with essential tremor, and over the years, probably treated thousands. It's the most common movement disorder, but probably grossly undertreated. I agree with the suggestions that have been put up there in terms of the market potential for this drug.
Yeah. Bill Ondo, so a movement disorder specialist for about 30-some years. I've been involved with essential tremor pretty much my whole career, and past president of the Tremor Research Group, helped develop the TETRAS, and have been involved with a number of clinical trials over that time. I'm sure I've seen over 1,000 patients with essential tremor as well.
Okay, great. We'll start the first part of it. We'll do a couple parts. The first part will be the current treatment landscape and the unmet need here. We've touched on some of it, but it'll be great to hear from your guys' perspective. I was just wondering how a typical treatment journey kind of looks like for these patients when they come in.
Yeah. So, a typical treatment journey will be, they will come into the office, we will get a good history. As you saw from some of the data, the vast majority of these people do have a family history. That creates an interesting dynamic, because I think that there is, in the landscape, and you guys have a tremendous opportunity, Praxis has a tremendous opportunity to shift this. There is a certain amount of therapeutic nihilism with essential tremor, because the drugs that we have available for it are lousy. They have a lot of side effects. We cannot use them in a lot of the patients. The people have often seen their parents, or cousins, or uncles and aunts, and how they have sort of had to deal with it.
A lot of times, they come in sort of late in their disease because they saw that, "Well, my parents did not do so well. I am hoping there is something new." It is really exciting now to be able to tell somebody, "Yeah, there is something new, and the data looks really good, and we are all really excited about it." But most of the time when they come in, we are going to give them propranolol if they can tolerate it, and that is a big if for a lot of the patients. The patients have a varying response to propranolol, from modest to the occasional patient gets a really good response. We sometimes do see that. But I think with time, as the data suggests, for many of the patients, the benefit wanes.
We will often add on primidone to the propranolol when the response begins to wane, but primidone is a tough drug for a lot of people. It has barbiturate metabolites, and so it causes a lot of people to feel sleepy. It causes a lot of people sometimes to feel not as sharp cognitively. So, a lot of times people do not like that drug. It is often difficult to keep people on that drug. Propranolol, with time, we start to see the benefit wane. We try to push the drug up, but as you push the drug up, you then start to run into tolerability issues. One thing that was not mentioned, and I think it shows you the burden of essential tremor, is once we start getting into that area, then we start talking about surgical procedures, which really were not discussed today.
So, I am able to convince people to have a hole drilled into their skull and have wires placed into their chest. That is the extent of the burden of disease when it gets bad enough for them, or they get their head shaved and put into a special type of MRI that then burns a permanent lesion into their brain. So, imagine my opportunity as a physician to now say, "I have an oral medication that I can give you that has really good safety and efficacy data." So, I think that it is really also going to shift the surgical market as well, once we have that. Bill, what is your-
Yeah, I agree. These days, probably the majority of people that come to me have already tried primidone and propranolol, maybe topiramate, maybe even BOTOX, a few other things that we try sometimes. They are coming really specifically for surgery, attesting to how problematic the tremor is to them. The surgery, to be fair, is very effective, but it is a big deal. You are either sticking electrodes in your brain or burning a hole in your brain, and those are pretty permanent situations. Again, the side effects are pretty manageable, typically, but that is really what we are left with as the next step these days.
Yeah, honestly, even with the patients who have really bad tremor, who I think are surgical candidates, a lot of them just say, "No," and suffer.
Yeah. No, that is true. As you said, there is some nihilism, and some of it is because the tremor so gradually increases over time, and this is a strongly genetic, although very elusive genetic condition. "Oh, everyone in my family has tremor when they get old." I could just imagine the commercials here, "Tremor is not normal," this sort of thing, "See your doctor." I think that will be very effective, actually.
Are patients just pleased that it is not Parkinson's, so they just deal with it? Is that what happens a little bit? I assume a lot of people, when they first start feeling it, worry that, "We have Parkinson's here.
Yeah, there is that population. In fact, yesterday morning, I had one of those patients that had a very mild tremor in their non-dominant hand, so it wasn't that disabling to them, and they just wanted to know they didn't have Parkinson's, and were happy with that. I would say that's a minority of patients that we see.
I'd say in my population, again, so when I use the term MDS, that means movement disorder specialist. As an MDS, we tend to get the more complicated patient or the more informed patient. I would say in my group, that's actually a pretty common question in the folks that I see. They're scared they have Parkinson's, and they're relieved when they find out they don't have it. We always, at least I always discuss treatment with those patients, even if they found out, "Okay, I don't have Parkinson's. I'm glad." Sometimes those patients will say, "Okay, that's all I wanted to know," and other patients will say that, "No, I want treatment." I always offer it when they come in.
Okay, great. We talk a lot about the 2 million patients, whether they're diagnosed or not, but they're the ones that are seeking treatment. Can you talk about essential tremor and when does it kick in? Are these patients seeking treatment the younger patients, or? Because it seems to me it's a progressive disease. You would think older patients have it worse, but I can also see how older patients are just like, "Look, I don't like the options out there. I've been living with this. I could deal with this," being a little more maybe even stubborn about it. Who are these patients that are seeking treatment?
Well, yeah, I think this varies. If you're a cardiovascular surgeon, the very slightest tremor might be quite problematic to you. By the way, everyone in the room has tremor. 100% of people have tremor naturally. It just gets to the point where it's problematic enough or large enough to cause problems. So, there's extremes, yeah, very minor tremors sometimes. Then, as Dan alluded to, there are some people that come into our clinic just like this, and I just don't know how you've survived this long without treatment, but they've been fairly reticent to seek treatment. So, it's a big spectrum.
Yeah, and when Bill says 100% of you have tremor, he does not mean essential tremor. He means tremor in general. Most of us have certainly an enhanced physiologic tremor, right? You all remember that.
100%, Dan. 100%.
Right, when you had to take an exam, or you had to meet with your boss or whatever, and you are all shaky, maybe you had a little too much coffee and that. Tremor is incredibly common. I would say my panel of essential tremor patients really runs the gamut. You have the younger person who has seen their parent or cousins, and sort of like the family curse. They tend to come in just because they want reassurance. You have the patients that you mentioned before, the ones who Parkinson's disease is really becoming almost like an epidemic right now, and it is really in the news, and so people are very concerned. So when they get a tremor, they are like, "Oh my God, I have Parkinson's." So they do come in a lot.
Then you have the patients who, as Bill said, the ones who have sort of been living with it, they may have seen their family have it, and it has gotten to the point where they cannot tolerate it anymore. When you look at the things that the TETRAS measures, and these are things about human dignity, right? They really involve. Imagine, you are all in business, right? You go to these sort of meetings. You were sitting in the back there. If you had essential tremor, while everybody else is eating their meal and conversing and socializing, you are probably not. You are sitting there because you do not want to have this in front of them and spilling your coffee. You do not want to have this and having your food fall off, embarrassing. You do not want to have shaking and dropping all over you.
And so it really impacts things that you don't even think about. I think people get to that situation where it's impacting their social life. It makes it hard to date and things like that, if you think about it. If you're going out and the only thing that sort of releases is go to a bar and have a drink, because that will dampen your tremor, because alcohol works. You really have to think about what you're going to do. A lot of social things are like, you go out for meals, right? You go have coffee. If you're an essential tremor patient, that's a disaster. The caffeine's going to worsen your tremor, and it's embarrassing. It really goes a lot. Things that you don't even think about. Buttoning your shirt, tying your shoes, stuff that we all take for granted.
If you even have modest essential tremor, those things start to become really difficult, and people start doing things like, "Well, I'm going to wear slip-on shoes. I'm going to not have shirts with buttons," stuff that. They have to start living their life that way. It's impactful. Again, it gets to things that compel people at a certain point, "I want to do something about this." As we sort of had pointed out, the current options that we have just aren't that great. That's why I think there is this therapeutic nihilism that emerges.
Okay, great. Do you think the patients, from their perspective, view it much worse than their physicians, or is it the opposite?
Well, yeah, I think it goes both ways. Like I said, there are people that come in that I'm just amazed that they can do anything at all with their hands. To me, I guess it seems much more problematic than it has of them, because I'm the first doctor they've seen about this. Then other people, again, are very worried about very minor tremor. Occasionally even what we consider physiologic tremor. I think there's a big spectrum there. I think in primary care physicians, they don't really think of essential tremor as much of an issue. It would be the same sort of thing. "Oh, congratulations, you don't have Parkinson's disease." Not realizing just how severely disabling the ET can become.
I think because our treatment options have been lousy, unless you are an MDS and you see a lot of essential tremor and things like that, there probably has been a lack of recognizing the seriousness of it to patients, and it is really more the patients demanding, like, "This is impacting me." As Bill pointed out, I think a lot of times, even in the physician's mind, "Oh, it is not Parkinson's. You are good." Not appreciating the fact that, no, you are not good. This really does impact people.
Okay. Can we break down, like some diseases, it is really unclear what is mild, moderate, and severe. With essential tremor, when we talk about the patients that are seeking treatment, is it fair to assume those are all moderate and severe? I guess it is a two-part question. What part of the population that you see, what do you think the breakdown is, maybe in your practice and out there, of mild, moderate, severe? Do you think there is a chance mild patients would actually seek treatment?
Well, I think in our practices, we tend to get the worst cases. I mean, that is just the nature of we are sort of the last stop. I think that there is an enormous opportunity, and I draw the analogy, I noticed that two of the drugs that you put up there earlier were Ingrezza and AUSTEDO, which are for tardive dyskinesia, and they have been pretty successful drugs. If you think about it, many of the people with tardive dyskinesia do not even realize they do not even appreciate it because the schizophrenics have a certain amount of anosognosia to their disease. Nevertheless, it has impact, and there has been a lot of education around that about, do not wait till somebody is tardive dyskinesia is horrible, right? Even moderate tardive dyskinesia can have real impact on people. You are not just treating an AIM score.
I think essential tremor is really, really analogous to that, right? What might look to me as a physician as really minor tremor might have tremendous impact on a patient. As Bill said, if you have a career that involves fine motor skills, if you have things that you would not even think about, but if I enjoy a hobby that is really meaningful to me that involves fine motor skills, and there are a lot of them, even though that tremor might look like, "Well, that is not much," yeah, but it is really taking away joy from my life. I like to build models with my grandkids, and I cannot do it anymore. Things like that.
I think particularly if we have an effective medicine with a good safety profile, that opens up a tremendous opportunity to stop thinking about mild, moderate, and severe, and think about more what's the impact on the patient rather than what I think, what my judgment as the physician is of this tremor. It's more about what the impact of that tremor is on that patient, and even if it's a mild tremor, if it's having an impact, I can treat it.
Is it fair to say that it always progresses? You don't get a patient that's just, "I've been mild for 40 years, and it is what it is." Is it progressive that obvious, or is it
In most cases, it gradually progresses. That being said, there's a bias here because if someone has mild tremor their whole life, I'm probably not going to see them. Okay. But the overall course is gradual progression over time in the amplitude or size of the tremor, and that's what causes the disability.
Okay, great. We've talked about propranolol and primidone quite a bit, but I just want to kind of, if you guys can share maybe what proportion we get that you guys are kind of the last stop, but what proportion of your patients have tried propranolol or primidone? How do they respond? How long do they typically stay on it, and why do they stop using it?
Well, I think, yeah, almost everyone has tried propranolol that comes to me, because even primary care physicians, I think, are comfortable with propranolol. Primidone less so because it is a complicated medicine, and there are some tricks to using it, and there are a lot of drug interactions you have to worry about with primidone. So, I end up starting primidone a decent amount, but more than 50% of patients that come to me have already tried both. Stopping it, honestly, usually it is just lack of efficacy, okay? In my experience, more than side effects, it is just not adequate at this point.
Yeah, I agree, and then there is a whole host of other ones that out of desperation, we sort of throw at people. Sometimes you see a benefit, but there are a lot of side effects. We will use topiramate, but the problem is once you get up to effective doses of topiramate, it either makes them cognitive, it impacts them cognitively, or they start to lose too much weight, which can be very problematic. We try gabapentin with very, very modest results in most cases. Use zonisamide off-label, but that is when you are He is smiling because we are really-
You are listing all these studies that I have authored.
Yeah.
These other drugs we try, generally unsuccessfully. Yes.
Yeah. So, that is what we do. I agree with Bill. I think most people stop it because they are just not getting a benefit from it, or to get any sort of benefit, we start pushing the drug up to the point where they are starting to get lightheaded or bradycardic, and they just cannot tolerate.
Okay, great. Obviously a big population here, but I think sometimes I will speak to physicians, and they are like, "Well, whether it is 2 million or 3 million, what is the big deal?" I think to most people in the crowd here, it is a very big deal, what 1 million patients can do, and we saw some of the market data there. Can you explain maybe why there is such a gap between the prevalence, whether it is seven, now it looks more like it is a nine that can grow, between the prevalence there and the seeking treatment? Do we think that gap with the new medicine, if Ulixa gets through the finish line here, could close quite a bit, and you see the promise of that 2 million seeking can really turn into a four or five, six, and honestly, with DTC, there is no limit here.
Yeah, I think you just need one Super Bowl commercial to take care of that. To me, the precedent for essential tremor would be restless legs syndrome 20 years ago. RLS is a similar epidemiology, very, very common. It was extremely underdiagnosed. Most patients that had it, like essential tremor, do not know the name for the condition that they have. All those medicine, or four FDA-approved medicines came out pretty quickly. They all did extremely well, much better than anticipated. I think ET would be pretty similar. I think it is going to kind of come out of the woodwork, especially with direct-to-consumer advertising. As a physician, I always cringe when I recommend that, but I got to say, I think it would be a very effective strategy.
Yeah, I think actually RLS is a great analogy because REQUIP had relatively modest use in Parkinson's disease, and then it exploded as a drug when it basically created RLS as a disease. We knew it was all out there, but we were not seeing these patients. I think it really shifted. I think Ulixa has the potential to do something like that as well. I think as you get more education, I think that will drive patients. I think part of the explanation of the gap, though, is what I went to earlier, in that, because so many of the cases do run in families, they saw that their cousins or their dad or mom tried the medicines, did not do anything. It is not Parkinson's, I am not going to do anything about it, because they did not have a good experience.
I think, birthday boy is in the crowd, and Super Bowl commercials are dirt cheap, so that's good.
Timing's perfect too.
Yeah.
I mean
I would also say do the commercial at the start of the game, because if alcohol has an impact here.
Yeah, exactly. Yeah.
Yeah. So, all right, good. If we go in maybe the data a little bit, I think, when the data came out, maybe October 15th or so, I forget, but 16th. 16th? Do you remember, Marcio? Wow, okay. That is a. Might not be awake. Yeah. So, when that data came out, I think, people had tried a similar MOA and stuff, so I think there was some shock, surprise, about the kind of P-values and efficacy that we saw here. I was just wondering, from your perspective, from speaking to docs, I have seen quite the evolution of when the data came out, people were like, "Let me digest this." So, maybe how clinically meaningful do you think this data is, and has your opinion here evolved since the presentations at AAN and just with time here as we have been able to digest this data?
I have no idea if this is the case, but maybe one of the reasons I was invited to come up here is, I was a real skeptic. I had questions about the trial design, I had questions about discontinuation rate, I had questions about scales, and then I saw the data. I had the opportunity at an advisory board to get into some of the other issues a little deeper, and my opinion shifted. I was somebody who was like, "Wow, I had not thought through that as much as I probably should have." Rather than doubting the trial design, I became a believer in the trial design. I think, and we can talk about this stuff a little more if you want, I think I came to understand the discontinuation issues, and I was really impressed by the data.
I shifted from a real skeptic to a believer, and I think that there is an opportunity for the company's standpoint when it comes to education for the HCPs. First, just to step back from that, I think the vast majority of HCPs who are not like MDS and really questioning things, stuff like that, they will not need it. They are just going to be so excited that there is a drug out there, and they are probably not going to know about, get into the data real deep. But for people like me, I was really impressed. I think so, and probably MDS will sort of be the people who drive prescribing initially, because they want to say, "Oh, what is Dr. Ondo doing? What is Dr. Kremens doing?" in your areas, and then if they tend to start to follow what we do.
I think that there's a real opportunity with the company to educate the MDS community who may still have some doubts. I think that that will drive adoption.
Yeah, I agree. Maybe that's why I'm here too, because I was fairly skeptical when I heard about the trial design. It was extremely innovative, very novel, extremely efficient. I mean, frankly, pretty clever in retrospect. They got a lot done in a fairly short time. I always worry about novel with things like the FDA, because they sometimes don't like novel. I think looking back in retrospectively, it was an extremely clever program. I just wanted to take one second to tell you what a point means, because we see these four points improvement. So what is even one point? I mean, the scale has large increments. A four means you cannot do that, no matter what. I cannot use a spoon. I cannot eat.
If you improve one point to a three, that means I can now do it with modifications, okay, maybe two hands, but I can do it. That's a big change. If you go from a three with modifications to a two, one point, that means now I can do it normally. I still have some disability. It's still a problem. I still may spill a little, but I can do it. If you do one more point from a two to a one, it means I have no problem whatsoever. So one point is a big difference in quality of life with these tasks. I think, one point may not look like that great a deal on a graph, but it really does make a big difference in quality of life.
It means I'm getting that second date after I didn't spill everything on the table.
Not with me, though.
All right, that is helpful. Because I think the ADLs, people are used to it. It is tricky because there has not been much out there, nothing developed for it, and people try to understand what a point is. But from what I am hearing, when you speak to the patients and they really break down what a point can mean, whether it is a second date or not, it seems like it is a big deal in their life. How do your peers feel about the ADL versus mADL, or are they just kind of like, it does not really matter which one you look at?
Well, amongst the ADL, there are 12 questions on the total on the TETRAS, and one of them is about social impact or are you embarrassed. For some reason, the FDA does not like that. I do not know why. But that is the only difference there. There are some other statistical things that were at the request of the FDA. The scale was actually compressed a little bit. But I think we all agree the activity of daily living component of the scale is the most important. Now, as one of the guys that developed the TETRAS, I mean, I still kind of like people sticking their hands out and us measuring that. But from the FDA's perspective, and I understand the argument, people do not normally go walking around like this in public, so it is less important than quality of life measures.
Honestly, this is what I was getting at before, and no offense to Bill as somebody who did develop the TETRAS, but ultimately, from a patient standpoint, they do not really care about this. They really care about, "What am I able to do?" I think we are seeing a shift with FDA, not just in this disease state, but certainly in Parkinson's and stuff like that. They are looking now to patient-oriented scales and outcomes, and I think that is what we are going to see with this drug. Personally, it matters more to me in terms of how the patient responds and what they are saying in terms of their activities than what I think about the tremor. That is how I approach it.
No real debate on clinical meaningfulness. The data
This data is clinically meaningful, and I think, honestly, certainly for your general neurologists and stuff like that, they are not really going to care about the scale that much. They are just going to care that the FDA has approved this drug for essential tremor, and we now have something other than propranolol and primidone. I think that alone is just going to create tremendous excitement. There has been almost 50 years since we have had anything besides drilling a hole in someone's skull or burning a lesion into their brain. Frankly, I am excited about the opportunity to talk about a new medicine rather than sending somebody for a surgical procedure, which is generally safe and effective, but it is still a surgery, and that is a big deal.
Especially with the older population.
Yeah
Sometimes. Yeah. Maybe the data here that was There was a lot of questions on durability, and we hear that with propranolol. Today, we just saw the data at week 95 on the durability going to, I believe it was 6 points. That is the first time we have seen this. Is this kind of shocking, groundbreaking, or is it like, "Look, anyone that worried about this is it. There is no issue with durability. If anything, this is getting better here with time.
The first time I saw it was last night, so I haven't developed too much of an opinion. I don't think it's shocking. I mean, it's reassuring, certainly, that there's no long-term side effects. Again, the main point in these long-term studies is safety, because everyone's on the drug, there's no placebo. The efficacy, you do have to take a little bit with a grain of salt. But it is nice that you still didn't lose it over time. If anything, it was a little bit better.
Yeah, and same thing for me. This is the first time I've heard a little bit about, but this is the first time I've actually seen it, two minutes ago with you guys. What I would say about that I think is really compelling, is just from somebody who's done studies, the fact that you have people remaining in an open-label study for two years, that in and of itself is telling, because it's very easy to drop out of an open-label study. And so when people stay in open-label studies, it suggests that the drug works. And the fact that they had that and that they have seen improvement, as Bill said, these are safety studies, so I don't necessarily get so excited about the numbers because it's open label. Everybody knows they're getting drug at that point, so you do hope that the number improves.
If it doesn't, then you've got concerns. But the fact that people are just staying in the study, to me, actually speaks more to the efficacy than the actual number.
Okay. You mentioned, because we're both two skeptics, and so interesting, you mentioned discontinuation, a lot of discussion around discontinuation. I guess the question is, are we still concerned about the discontinuation rate, or is this something with titration and compared to propranolol and primidone, if you compare it to what's actually out there and used, this is fine? How do we feel about the discontinuation?
Yeah, it's a little hard to assess because again, this was one of the criticisms of the study, that there was a prediction they would have a higher discontinuation rate because this was this decentralized study. Patients didn't come to my office, shake my hand, look in my eyes, get reassured about being in a study. There was just a little less skin in the game for the patient. That was one of the predictions, there would be a relatively higher discontinuation. I can't tell you what percentage of it would have been if it was a more traditional study. We don't have a lot of. There's so few large drug trials with essential tremor.
One of the few that was published was my trial 20 years ago with topiramate, and the discontinuation rate was about the same in that trial as it was with this trial. There's not a whole lot to compare to.
Do we think, just to touch on the titration part, do you think this is something where in the real world, people will look you in the eyes and you'll get a chance to titrate? Is it something you expect just to be better in the real world, or?
I'm not concerned at all about that. We've seen that. I mean, there have been other analogies recently, again, thinking about a drug like Ingrezza. The recommendation was that you start at 40 mg, and then after a week, you go up to 80 mg. We did that in the real world, and we ran into some issues. Then very quickly, we learned that you can do this drug slower. All the side effects went away. We saw this with Gocovri. 20% hallucinations in the trial, but in the real world, where we dose it differently, I barely see hallucinations with the drug. I'm not concerned about that at all. I think if we have the ability to, as clinicians, we can do what we want, and we'll learn that, and we'll titrate appropriately.
I think the other thing is, I didn't know, I just learned right now that Bill was a skeptic along with me. I didn't know that. I think the fact that you have two skeptics who, when actually got a real chance to look at the data and think about the study design, says something. The other thing, I agree with the study design, right? That's in terms of that, when I really thought about it, that reassured me in terms of discontinuations as well, because this was done during COVID. It's very easy to say, "You know what? I'm tired of this person coming in my house. I don't feel comfortable anymore." Because that's what they would do, right? They would come to your house.
It's just sort of very easy to get in the site, but very easy to get out, as opposed to coming into my office where you have to look at me and tell me you're dropping out, and then I, "Oh, come on, give it a try," and I can talk you into the study. Didn't really have that opportunity in this study. I think that really explains a fair amount of it as well.
That's funny. Like breaking up over the phone's a little easier or something.
Exactly. That's it. They ghosted me. They sent me a text.
Breaking up over the I thought it was just a text now.
Yeah. Okay. What I think is really interesting about the trial is I think 30%-40% of patients were actually on propranolol in the trial. I guess the question is, how do we anticipate using ulixacaltamide? Is it monotherapy? We hear about people saying, "I'm going to add on to propranolol, and then I'll kind of taper propranolol off." Or is it total switch or just one at a time? How do we expect to use this? If you guys expect to use it here.
Yeah. No, I think it could be any of them. I mean, what's important is the mechanism of action is unique. So, it's not going to be redundant if you add it to propranolol. They're working different ways. Propranolol basically blocks adrenaline. Adrenaline makes tremor worse. So, I don't think there'll be many patients on dual therapy, maybe even triple therapy, potentially.
You would expect them to be on because of different MOA?
Yeah, as long as there's a different MOA. I would never use two beta blockers, nadolol, propranolol. That's redundant. But as long as there's a different mechanism of action, it's rational sense to use them as well.
Would you try to taper off propranolol or, look, if they're fine and they're
Yeah. I will, again, probably all the above. I'll assess whether I think the propranolol is really doing anything. Right now, we keep people on propranolol because we don't really have options. I think this is something that we'll get experience with. I mean, I think the big challenge, initially, we're going to just have to see what they require in terms of step-throughs and things like that. I mean, frankly, I would, given my experience with things, I would love to use it as initial therapy, and I'm hoping I'm going to have the opportunity to do that. We'll see when we get into, that's going to be up to these folks to solve those problems for me.
Another thing, there's a tremendous opportunity for the companies to do this, and I don't think the companies are doing, and this isn't a criticism of Praxis, it's a criticism of pharma in general. Patients do not know. I have this talk every day. Patients do not know about the Medicare payment plan or smoothing. This is a tremendous opportunity for a drug, if it's going to be expensive, it's a big deal for most Americans to have to come up with $2,400 in January and February, right? There's a study that shows that the average American can't come up with $400 if they need to. But with smoothing, they'll be able to get it from day one in January if they can come up with $200 a month.
I think pharma should really be doing a better job about educating patients about this, because a large number of your patients are going to be on Medicare, and this will be a way. It will make my life a lot easier. I spend several minutes with every one of my Medicare patients during an appointment talking about smoothing, and none of them know about it. I actually think pharma, the organization, you guys should all commit money to making advertisements to tell patients to do smoothing. Anyway, that is my editorial, but I think it will help you get this drug used.
Okay, great. In terms of the, I guess the question that comes up quite a bit here is, we have seen numbers, but among diagnosed or treatment-seeking ET patients, this is that 2 million that we talked about, seems like we agree that this could grow. Is that fair? Yeah. From that, what proportion of your candidates do you expect to try this at launch? To be clear here, it is not just prescribe, because some people drop off sometimes, but what percentage of your patients would you expect to be on this in the first 12 months? Do you expect that to grow much? What would be the percentage four or five years down the line here?
Well, I think we are both early adapters as-
Right
as I said. I do not see a lot of reason not to try this medicine as long as we can get it in anyone that has residual problematic tremor. I mean, the only population that we see on a regular basis that I think would not do it are the ones that already have deep brain stimulation and their tremor is adequately controlled with that sort of thing. Just about anyone else that has a problematic tremor, I think you could try this on.
Yeah, traditionally with medications, I have been an early adopter. I will be an early adopter of this if it gets approved. It will be the majority of my essential tremor patients. I think what will happen, at least with my population, is that there will be a big spike in scripts, then once I have converted or added on to my population, then I will sort of slow down, then it will just be the new patients coming in. I think that that is probably what you are going to see in the MDS market. I think as it expands into the general market and then into primary care, I think at that point, the sky is sort of the limit in terms of because they see a lot of folks before I do.
Because getting an appointment with me is very, very difficult, I think that down the road, as people become more comfortable with the prescribing thing like that, I think there is tremendous opportunity in primary care.
Yeah, we have ran a bunch of surveys, and we have talked to a lot of people as well, where we have heard these numbers of maybe 50%, 25%-50%. What we saw today, I think, was from their survey, was 36%. When you see that, are you surprised, or is it kind of like, "No, that is kind of what we are seeing, and we think this could actually grow with time here"?
I am not surprised because a lot of physicians, and particularly neurologists, tend to be cautious people. I think Bill and I may be a little anomalous in that regard in that. I do a lot of work with pharma. I have done a bunch of trials. I have a lot of confidence in how these things are done. I think when a drug goes through the rigorous process and then I am ready to use it. I think other people are one of my partners at work is, he waits to see how I do it for like six months, then he says, "Okay, I am ready." That is it.
Still a lot of bow tie-wearing people in our field.
Yeah.
People kind of follow your lead a little bit. But when you talk to other physicians here, are people aware of this PDUFA date and the potential for this to happen in January? Have you seen an evolution, or is it like, no, only the ones in our situation really know what is going on here?
Not sure if I have a good sense of that. I have had a couple patients that have come in, having heard about this medication. I do not have a good sense.
The patients, right. But how about the physicians when you speak to peers and stuff, or?
Yeah, I'd say that, again, we're a little bit biased in that, in the MDS world, it's a small community, and we talk a lot. I think there's relatively high awareness, but not necessarily a lot of literacy. I think they're aware there's a drug out there. I don't think many of my colleagues don't even know what a PDUFA date is.
Yeah, I've made that mistake of expecting them to know.
They have no clue.
Yeah.
They're just, "Oh, it got approved?" They don't understand that. They don't follow it. I'm very interested in this stuff, so I do. I would say that there's, again, a lot of opportunity for education in that regard. But among us, there's awareness. Among the broader population, I don't think there's enough awareness.
From Marcio's mouth, "If you're illiterate, get literate," is the comment.
Exactly.
To expand beyond, is there any precedence here to expand beyond the MDS kind of docs to go into the community neurology? What would drive kind of broader use here? Do you have an idea of how that would progress there?
Yeah, no, I think so. I mean, essential tremor, I would say a relatively larger percentage of patients with essential tremor compared to, say, Parkinson's disease are seen by general neurologists. Certainly, I would say the majority of people with ET. So, it's going to be imperative to seek out that population from day one, I would say. I think that's the plan. I mean, there's about 15,000 neurologists in the country or so. So, there's not like a million of us to try to reach.
Yeah, and honestly, again, because I've done a lot of work with other companies, particularly in the Parkinson's space, including some smaller companies. Again, I just saw this stuff for the first time. We were sort of talking last night, and I didn't even get this because I guess they wanted to show it publicly first. I think the notion of, in terms of like this, that you guys already have so many sales force hired, that's larger than some of the smaller companies in the Parkinson's space. I think I was really impressed. That gives me a sense like, wow, they're really serious about getting this out there.
Clearly, I think we've come to an end here. I just wanted to make sure, is there something that I should have asked that hasn't come up that's been on your mind? Whether it's, I think we touched on the data, we touched on the commercial opportunity, we touched on the initial skepticism. Anything where you're like, "Wow, that was a terrible job. You should have asked this question.
The only thing that I would add, and I don't know if this is something that the analysts think about or not, but I'll add this for reassurance. I think sometimes people get worried when they hear specialty pharmacy. I would just say that in the past decade, neurologists, many, if not most of our drugs have been specialty pharmacy. This is something that we deal with routinely. We are comfortable with it. Not just the MDS guys, but the general neurologists, in fact, the general neurologists deal with it much more. I don't have to worry about multiple sclerosis. I don't have to worry about myasthenia gravis. I don't have to worry about headache. I don't do that stuff. But the general guys do. They're seeing specialty pharmacy all the time.
If you asked me five years ago, "Oh, specialty pharmacy, blah," that's done now. People don't have that issue anymore. I don't think that's a concern, if anybody was thinking about that.
If you really can just type this into Epic, into your EMR, and then have other people take care of the rest, yeah, that would be awesome.
Yeah.
All right. I think that closes out this panel. Thank you very much.
Thank you.
We will take a brief break for 10 minutes. See you back at 10:20. Please make your way to your seats as the program will re-begin shortly. Thank you. Please make your way to your seats as the program will begin shortly. Thank you.
Hey, everybody. Welcome back to the session. We're going to turn our attention to relutrigine now, our precision medicine for developmental and epileptic encephalopathies. This program is important to me because it reflects many of the scientific principles on which the company was founded, understanding mechanisms driving neuronal hyperexcitability, and designing medicines that target those. Relutrigine has delivered positive clinical trial results in children with SCN2A and 8A encephalopathies, and I'll explain both the results and why we believe the opportunity could extend well beyond these two genetic diseases. The idea is really quite simple. Regardless of what initiates the disease, seizures ultimately depend on the ability of neurons to generate action potentials. In SCN2A and 8A DEEs, the sodium channels themselves are mutated. In many other DEEs, the primary defect lies elsewhere, but abnormal network activity still depends on sodium channels to sustain pathological firing.
That distinction is really central to our strategy. We believe relutrigine can target the abnormal electrical activity rather than needing to target the specific genetic mutation responsible for it. For children and families that are dealing with this, these are among the most devastating neurological disorders in medicine. Seizures begin in infancy, often amongst the first weeks of life. They are refractory to one medicine after another, and they come alongside profound developmental delay, and for many of these children, a shortened life. I want to draw your attention to a statement on the slide because it is one I would ask you to hold onto. No medicine has ever been designed for these children, not one. Everything they take was developed for adults with common epilepsies, and none of it has been formally tested in this population of 2A and 8A kids.
What follows from that situation, and I do not think it is widely appreciated, is there is no agreed treatment algorithm. A physician seeing one of these children is working from personal experience, often from a handful of cases across a career, choosing among adult medicines and titrating and testing by trial and error. Families move through drug after drug, each with its own side effects and its own administration burden, and in most cases, the seizures continue. This is the standard of care today, and it is dire. When we talk about what we are trying to achieve, reducing seizure counts matters, but it is not the whole situation. We want to know whether better control of neuronal activity also delivers gains in alertness, communication, behavior, and everyday function. Parents want to be able to interact with their kids more than they have been. Those were the children that relutrigine was built for.
As I said, no medicine designed for them, and their families are working through adult drugs. The selectivity you have seen in the properties of relutrigine, that I will talk about more in detail, is why we believed we could do better, have a stronger control of pathological firing and a tolerability that allows us to dose to the maximum of efficacy. So EMBOLD is where we put that to test, in children with SCN2A and 8A developmental encephalopathies, and it is the first positive study in these disorders. The outcome was compelling, and importantly, the benefit was not confined to seizures. These were severely affected children. About two-thirds of them were on three to six background medications. Baseline burden ran to a median of roughly 55 seizures a month, with many children having over 100. Conventional pharmacology had already been tried here, and it had failed.
Before the results, look at the schematic on the right, because we are showing you the placebo arm design for the first time. I know there has been a lot of discussion over this over the last two years or more. What you will see is that the double-blind phase ran 16 weeks in four four-week periods. Children were randomized one-to-one. The relutrigine arm was on active drug for all 16 weeks. This is the bit of missing information that we have talked about a lot, and we did not know, was that the placebo arm received placebo for the first four weeks. Weeks one to four, that was it. Fixed, pre-specified. Then relutrigine for the remainder of the 12. Same structure in both cohorts at the 0.5mg and 1 mg. We need to be clear about this design.
No one knew when the placebo period would be, and that was what we've been talking about. All sites, investigators, caregivers were all blinded to the design itself. Nobody at the bedside knew the placebo was confined to the first four weeks or that the switch came at week five. No one could anticipate the crossover, and nothing in the seizure diaries could be gleaned from that. It's a strong design, and it's deliberate. The placebo window was designed before anyone was dosed, so the comparator is the same four weeks of trial time for every child. Because the relutrigine arm was on active drug across those same weeks, the comparison is randomized, concurrent, and parallel group. The four-week limit was an ethical requirement, not just a statistical convenience. These are children who can die, and some are already lost during screening before they ever receive a dose.
In that setting, every additional week of placebo is another missed week of opportunity to control seizures in a child that's at real risk. Four weeks was the window that yields a stable 28-day seizure count, and we were not willing to make it longer. Every child was on relutrigine following that. If you look at the results, EMBOLD stopped for early efficacy. The endpoint was met at the interim analysis with a 53% placebo-adjusted reduction in motor seizure frequency and a p-value below 0.0002. The key secondary endpoint was also positive, showing 66% more motor seizure-free days than placebo. The magnitude and statistical strength supported early stopping for efficacy. These are not just directional findings, they are controlled evidence that relutrigine can meaningfully alter the seizure burden in this exceptionally challenged population. Just bear in mind, these kids were on maximum standard of care coming into the trial.
What I'm showing you now is new data. Cutoff, 14th of August 2026. This is the first time they're being shown externally. If you look at it, among patients contributing to the data at 18 months, mean reduction in motor seizures from baseline reached approximately 86%. 98% of eligible patients continued into the open-label extension. In this population, that figure says as much as efficacy does, and it reiterates the point discussed earlier about relutrigine, about ulixacaltamide. The cohort contracts, obviously, as you move out in time, because children enrolled later have not yet reached those later months. But 67 at month five, 49 at month 12, and 10 at 18. You can see the trend continues. These are patients that have been on the drug the longest, not a selected group of responders.
The fact is, the benefit has held and deepened in everyone we followed that far. The direction here is what matters. The effect is not decaying with time, it's getting stronger. Of course, as I said, seizure frequency is important. What are other benefits that are derived from reducing seizure burden? How many, and importantly for children and families, and we hear this time and time again when we speak to families, how many seizure-free days can they get back? That's a day without a seizure. That's a day where you don't have to disrupt your plans. It's a day when you can have a normal interaction with your child and your other children. You can be a family. Children on relutrigine experience an average of 17.3 motor seizure-free days per 28, compared to 10 on placebo.
That's roughly seven additional days that they get back without a motor seizure each month. The difference was statistically significant. There are days with less interruption, less uncertainty, and potentially more opportunity for normal family life. We'll see how that pans out in the extension studies and what happens with deepening seizure burden benefit, how that's impacted. Improvements across other domains. We asked physicians and caregivers to see what they could see beyond seizures. Both the clinician and caregiver global assessments favored relutrigine, with statistically significant treatment differences. The domain assessments highlighted improvements in alertness, communication, and seizure severity. Not only are we seeing a reduction in the number of seizures, each individual seizure that's happening is also less severe, and things that matter to parents. The ability to get your child's attention, the ability to communicate, is all significantly changing.
We're seeing 78% improvement in alertness in the assessments presented here. These measures are not just interchangeable with seizure counts alone, and that's why they matter. They matter, they suggest a broader functional signal, and it's exciting for us to see this sort of multi-domain impact of relutrigine. Big efficacies, great, but it's only useful if patients can stay on treatment. Relutrigine was generally well tolerated in EMBOLD, with no drug-related SAEs, no dose reductions required in the controlled experience shown here. This was achieved in children that are already on complex regimes, including sodium channel blockers already. This is very encouraging given the familiar tolerability limitations of less selective sodium channel approaches. We'll continue to evaluate safety as exposure increases. We've also designed relutrigine around the practical realities of caring for children with severe DEEs. Perhaps the most important feature here is once-daily dosing.
Our clinic advisors and KOLs have consistently told us that once-daily administration could be a game-changer for these families. Many of these kids are already taking multiple anti-seizure medications, often several times a day, with complex feeding and caring requirements. Reducing that burden to a single daily dose is a meaningful advantage. We've gone further. Relutrigine requires no titration or tapering, comes in a liquid formulation for oral feeding or feeding tube administration, and is compatible with ketogenic diets. These aren't simple conveniences. For families whose lives revolve around managing a child's disease, simplicity of administration can make an enormous difference. If we look at the five strengths that really define relutrigine's clinical profile, comes across in these dimensions: substantial seizure reduction, more seizure-free days, encouraging functional improvements, tolerability in a heavily treated population, and practical administration.
The results from EMBOLD establish why we are excited about relutrigine in SCN2A and 8A DEEs. They also motivate the next question: Could this mechanism help children whose epilepsy arises from very different genes? That's the scientific hypothesis behind EMERALD. What positions relutrigine for efficacy in EMERALD? EMERALD is done, it's positive in children whose sodium channel is mutated itself, so in EMBOLD. EMERALD asks the bigger question. Broad DEEs, more than 50 distinct etiologies, and in most of these children, the sodium channels are normal. We'll hear about the top line in the fourth quarter. The question's worth asking because relutrigine does not target a mutation. You can see it targets sodium channel behavior, whether it's mutated or not. I'll take you through the biophysics because that's what positions relutrigine for efficacy with non-sodium etiologies.
The first part of our argument is that regardless of the underlying mechanism, neuronal hyperexcitability ultimately converges on a common mechanism, the action potential generation at the axon initial segment. That is a specialized neuronal compartment loaded with sodium channels and a determinant of neuronal output. Different DEE mutations may disrupt inhibitory circuits, potassium channel, or synaptic signaling, but the results of pathological firing still depend on sodium channels, even when those channels are entirely normal. We have discussed this rationale before, but for today, we are actually sharing some experimental data that directly support it. In this series of experiments, we have used a method that we have tuned and deployed at Praxis called dynamic action potential clamp, along with traditional patch clamp electrophysiology, working on the human NaV channels.
We demonstrated here, if you can look at the center figure, that relutrigine reduces neuronal firing in normal wild-type channels by 80% with one micromolar concentration. What is really important in how you modulate sodium channels in epilepsy and other disorders, it really comes down to this property called availability. How many sodium channels are left after you give the drug? That is an important thing. For drugs that do not have any ability to tune that effect with activity, you reduce that available constantly, that availability. It is always down. For drugs that can modify the amount of availability according to need, can do that in a way where there is less impact on availability when the neurons do not need help, more impact on availability when they do. We have been talking about that as a functional state-dependent property of relutrigine.
That is really compelling, and what you can see in that middle. You can see here that we believe that is the reason that relutrigine is positioned so well. This is that hard data, the second part of our argument. If you look at that, how does it distinguish then between normal and pathological activity? I talked about availability being a common feature of sodium channels. Here, we see the signs that relutrigine tailors its availability according to activity of the sodium channels, and that is a direct correlate of activity of the neuron. The more you activate a sodium channel, the more activity it is supporting in that neuron. These figures show us that with increasing concentrations of increasing firing rates, relutrigine can have a different effect.
If you look at that panel on the right, you can see where there is low-frequency firing, channels have lots of sufficient time to recover between action potentials. But during rapid repetitive firing, the characteristics change. If you look at those, the impact of relutrigine is minor when the channels are participating in low-frequency firing and major when it is participating in high-frequency firing. That is the transfer function, that is the quality of relutrigine that lets it tailor to activity of the neuron and enables us to seek as much efficacy as we can, while maintaining a tolerable outcome during those periods when seizures are not happening. In many, many cases, in sodium channels in particular, tolerability drives the limit of efficacy. Here, we overcome that with this very, very unique biophysical property, and it is a really, really an important distinction.
It provides with a clear mechanistic basis for our preferential suppression argument. There is a third piece as well, and that is persistent current, and there has been a lot of discussion around that in the field. We will call it INaP for I sodium current that is persistent, and I want to make somewhat counterintuitive point here. Years of neurophysiological studies have led to the understanding that neuronal excitability depends in a non-linear way with persistent current. Once persistent current falls below a critical threshold, even a relatively smaller further reduction in that can have a profound change in the neurons. It is a threshold effect. As you move down and you cross that threshold, you really have a big effect on the neurons. That neuronal firing or intrinsic excitability, as we call it, is the substrate on which seizures emerge.
The more excitable a neuron is, the easier it is for that to participate in paroxysmal discharges that underlie epilepsy. An important consequence of that non-linear impact on threshold is that in neurons with normal levels of persistent current, as you would see in a wild-type neuron, that threshold actually is you are closer to that threshold at all times than you would be in neurons carrying gain-of-function mutations that elevate persistent current. That is somewhat paradoxical now, because those wild-type neurons carrying wild-type sodium channels are going to be closer to threshold, so it is easier to modulate them than it is those that might have greater levels of persistent current.
That is not something we have talked about before, and I think there has been some. That is something we have known from the literature, but we have not related until we actually got the data to show that that could be the case. You can see here, the evidence is totally consistent with that. We see at 0.3 micromolar relutrigine, we saw 60%-77% inhibition of neuronal firing in wild type and in two channels that carried mutations that cause DEE in these SCN2A kids. Not all mutations produce an increase in persistent current, and that is another important point to understand, even in the 2A cases. In some cases, we see a major increase in persistent current, and that is the cell shown in green. In that case, where this cell had a remarkably greater level of persistent current, its pharmacosensitivity to relutrigine was less, not greater.
That goes back to that threshold argument. You are further from the threshold, you need more reduction in that persistent current to take you to that point where that mechanism can actually help with firing. That is counterintuitive, but it actually has the. It is paradoxical, but it has the benefit that in the absence of sodium channel mutation, we actually have the situation where that is not a disadvantage. Mechanistically, it could be an advantage, and it is very encouraging for our EMERALD trial to have this property. If we look a little bit more about EMERALD, it succeeded its enrollment target. The baseline characteristics tell us two important things. We have recruited a population with a profound disease burden and one that represents extraordinary genetic diversity, as I mentioned, with over 50 different etiologies.
The median age is just 13 years, yet these children are experiencing 58 motor seizures every 28 days, despite taking a median of three background anti-seizure medicines. Many also have significant limitations in mobility, communication, and feeding. Importantly, that high baseline frequency provides a strong foundation for measuring treatment effects. With this many seizures, large apparent improvements are less likely to arise simply from random fluctuations in seizure counts, reducing one potential contributor to apparent placebo responses. As I said, the genetic diversity is remarkable. More than 50 distinct genetic etiologies, making EMERALD a particularly meaningful test of our hypothesis that a diverse genetic cause of epilepsy converge on a common mechanism of neural hyperexcitability, and relutrigine can address the majority of those. If relutrigine is efficacious in this population, it would provide compelling clinical evidence that a therapeutic potential extends well beyond sodium channel gain-of-function disorders.
With that, I'd like to introduce two of our esteemed colleagues, Dr. Smith and Dr. Segal, principal investigators for EMBOLD and EMERALD, and have been instrumental in advancing these programs. Joining them as moderator is Brian Skorney of RW Baird, who will lead the discussions.
Am I on? All right. All right, I got to warm up the crowd with a little joke to start. Why is it so hard to get an appointment with a neurologist? Because they're one in a unmyelinated. Yeah. I am a dad, so it's a dad joke. Doug, Eric, thanks so much for being with us here today. Really excited to talk about relutrigine and the DEE opportunity. Maybe to just start, you could each tell us a little bit about your practices, the number of patients that you see, the types of patients that you see, and what you're currently using as sort of the standards of care across DEEs.
All right, I'll get started. Hi, my name's Doug Smith. I'm a pediatric epileptologist, been in clinical practice for the last 10 years, all at Minnesota Epilepsy Group, which is a large private practice epilepsy-only group that has our own multiple level 4 epilepsy centers, and have been doing drug trials for a long time. I personally have done, this is my third novel molecule RCT in this specific space, and I've done a number of others as a sub-investigator. I started our genetic epilepsy clinic there nine years ago, and that field has went from a very niche thing to a very, very prominent focus right now in epilepsy. I've been involved from the beginning with EMBOLD, and yeah, happy to talk about it.
Great, Eric.
Okay. I am Eric Segal. I am a director of pediatric epilepsy for Northeast Regional Epilepsy Group, also a private practice epilepsy group, but based here in the New York, New Jersey region. We have a footprint that goes from Orange County, New York, down to Middlesex County, New Jersey. We run several different epilepsy centers, level 4 centers, both in pediatrics and adults. In addition to that, I am director of pediatric epilepsy for Hackensack University Medical Center in sunny Bergen County. In terms of my practice, I have been practicing for about 15 years. Also, since training, I have been at Northeast Regional Epilepsy Group. I have been involved in clinical trials since 2013. Our practice is unique. We do not cover any emergency rooms. Patients that come to us, they are usually second, third opinion patients.
A lot of these epileptic encephalopathy patients, families who are desperate to help their children, their quality of life, both from a seizure and beyond the seizure perspective.
Great. If I pull up treatment guidelines, there is just a whole array of ASMs out there to use. Given that, there seems like there is still a lot of room to treat these patients. Maybe you could kind of characterize, where do you see the biggest unmet medical needs across pediatric epilepsies?
Well, I mean, this is kind of the opposite of the conversation we just had with ET, where we have about 32 different approved anti-seizure medications, and yet one-third of our patients still have ongoing seizures. When you consider the DEE population specifically, you are talking 99% of them are still having ongoing seizures. In terms of a specific unmet need, I mean, obviously there is an efficacy gap that we are still looking for better seizure control with all of these individuals. I have always highlighted a formulation, a non-sedating formulation, since the majority of our medications tend to be sedating. There are a few exceptions, but in general, they tend to be sedating.
Frequency of dosing, a lot of the new formulations, one of being most of our medications are twice a day, unless you have an extended release version, which in children, most of them are liquid, so extended release versions are not an option. So once a day is a particular unmet need, and one that we will not be covering here. I still think that having any non-oral approach, particularly long-acting patch-based, depot-based, anything like that would be really transformative to our field.
I would say that there are two buckets in terms of unmet needs. One is with regards to epilepsy, and that could be broken down a couple ways. Then the other is really just, like I said before, beyond the seizure in terms of cognition, interaction, alertness, some of the CGI data that was just presented before. That is huge, because patients, it is either the seizures or the abnormal electrical activity in between seizures that is making these kids so encephalopathic. In terms of the seizure control, yeah, so most of our medications can be very sedating, so it is a combination of how do we significantly make a meaningful reduction in seizures without snowing a patient in terms of letting them be awake and alert and attentive. Sometimes we- Those items tend to be mutually exclusive. We can get one but not the other.
To have a treatment that can afford us both is kind of a breakthrough. For a lot of our DEE patients, they come to us already on several of these sedating medications, and we are adding onto it because a lot of these epilepsies are explosive. So they could be first few hours of life, first few days of life, first few months of life. So those patients are being exposed to heavy doses of IV medications from the get-go, and then we are left with trying to pull back on those medications and try to find a better bridge to help them both maintain or improve their seizure reduction, and then also try to get them to reach some of the milestones that we think that they ought to be able to reach.
Can you walk us through a little bit how you just kind of think about looking at the patient and then sequencing therapy? What are the major things to take into account? Is it genetic subtype? Is it type of seizure? Is it severity, frequency? How do you decide among the options that you have available to you?
Well, this is very artisanal, I think was the word I keep hearing over and over again. There is really very, very, very few situations where we have a secret sauce, where we have an agreed-upon paradigm treatment approach, sequence of medications. For me specifically, I personally find that in the neonatal period, we have our own specific subset of medications, but now I have in a non-structural neonatal, I tend to then very quickly go on to sodium channel blockers. I have many of my colleagues who are very uncomfortable using sodium channel blockers in neonates. I think that you ask five different epileptologists up here, you would probably get 20 different answers. It gets very, very, very niche. It even holds true even across specific genetic conditions.
Dravet syndrome is one of our better-defined genetic conditions, and even there, we still can't necessarily agree upon a single treatment approach. We have, this is our first tier, this is our second tier, this is our third tier, and we still fight quite a bit across those tiers. For me personally, it still further I really take the tier approach as well, but it also gets highly customized to the individual patient. You have very varying risk tolerances across this patient population. Anxiety runs very, very high in this patient population, and that anxiety is sometimes structured towards the seizures themselves. I am going to be reaching more towards medications that might have stronger side effects but have a better efficacy profile, or there is others that are more risk-averse to medications.
I am reaching more for medications that have a very favorable side effect profile, although they are not necessarily as beneficial in terms of efficacy for seizures. It is a really highly customized approach to each individual. I am really dodging your question there. I think that, again, it depends on the population, depends on the diagnosis, depends on the patient, but I certainly have a number of medications that are kind of higher up depending on the circumstance.
Yeah. I would say that sometimes syndromes and seizure types can be incredibly important. If you have lots of drop seizures, for example, then I lean in a certain direction. Lennox-Gastaut, Dravet syndrome have become very clear diagnoses. I would say that we code more now for Lennox-Gastaut than we ever did before EPIDIOLEX came, even though we had rufinamide before that. We have become a much more syndrome-based specialty. We are trying to find a more specific and precise treatment for those patients. I share some of what you said, but I would say, I think the setting also matters. Is it an inpatient setting versus an outpatient setting? Is it something that is acute that we need seizures to stop immediately because we are rolling into status epilepticus?
Or is it something where seizures are stably unstable, and so we have some room or latitude or runway to get the prior authorization, get the medication delivered to the patients? So it depends on where we catch the patients in that cycle.
Just when you think about sodium channel modulators in general, what percentage of DEE patients would you say are on a sodium channel modulator or took a sodium channel modulator, and what percentage of those wind up not on it because it does not work for them or not on it because there is a tolerability issue and they discontinue?
God, I am just thinking about this one. I mean, so we reach for sodium channel blockers relatively early in the treatment algorithm. Whether it is a focal epilepsy, they tend to be very, very early, both in pediatrics and adults. Even in generalized epilepsies, we will often use lamotrigine fairly early. I think that who does not get it? Well, people who are with generalized epilepsy that we tend to start early with KEPPRA, and also obviously with Dravet syndrome, we do not really use sodium channel modulators. So how many try it at some point? I guess the back of the envelope, 50%-60% at some point. I would say most of them, when you use them with monotherapy, are pretty well tolerated. Certainly, we both see a very selectively severe epilepsy phenotypes, and so we do not tend to get away too much with monotherapy low dose.
I would say in my population, side effect limits either my dosing of it or how many of them I can use at one time, maybe one-third of the time. Again, these are very rough estimates.
I would say the limiting factors for me is probably side effects and interactions, right? Because there is lamotrigine or oxcarbazepine that you just mentioned. I mean, these medications have so many other medications that they interact with, it becomes much harder to use. Levels are harder to get back quickly. That can be a great limiting factor. I would say that for a lot of our patients, oxcarbazepine is not our first choice unless we see some clear focality. We prefer to go with more broad-spectrum medications. Lamotrigine is a great choice, but the challenge is how long it takes to ramp up to get to a therapeutic dosing. Sodium channel blockers do have a role. One more thing is, mentioning Xcopri also, it is a medication we are using more and more, and it is a great medicine.
We need a long runway of time to titrate those patients up. If they are on concomitant clobazam, which a lot of our DEE patients are taking, then it could be a great combination, but it could be incredibly messy, especially in the beginning to use. We do use sodium channel blockers. I think we would use more sodium channel blockers if we have the right one. If we have one that we can titrate quickly, that has limited interactions with other medications, and the side effect profile is, we are not causing hyponatremia, Stevens-Johnson's, or DRESS, or something horrible, these other organ-related side effects that we have been seeing.
I guess when you think about if you had the availability of relutrigine today, does the sort of prior history of sodium channel modulation impact your decision to use it, right? If someone was responsive but couldn't tolerate it versus never responsive, how do you kind of think about where you would start?
Yeah, I think that is definitely something that would factor into the algorithm. I mean, that logic already holds for something like going from KEPPRA to BRIVIACT, where if they didn't tolerate KEPPRA but saw benefit, we would often go to a newer generation, similar class. The caveat there, though, is that we lump these sodium channel modulators together, but they're not all the same. I think we're going to be highlighting repeatedly, at least we're going to be highlighting once we see the Dravet efficacy here, that they're not all created equal. I think that it will drive, okay, well, yeah, they responded really well to oxcarbazepine, but it caused a rash or it caused hyponatremia.
I think that would prompt me to be more interested in something like relutrigine, but I think that while it may influence our prescription use, I think that we may over time find it's I think we even realized that earlier in the conversations. We didn't call it a sodium channel blocker. We've been calling it a sodium channel modulator. Up until recently, we only used sodium channel blocker. You'll see it across all of our literature. It's SCBs. It's even new linguistically for us to start calling them sodium channel modulators. I think it still will be in the conversation if we see efficacy from one of these other ones, that it would drive adoption or at least a trial of relutrigine.
Yeah, I would say that it started with XCOPRI when we were invited to do the XCOPRI studies. I don't think any of us were losing sleep waiting for another sodium channel blocker, like you said. We had enough, and we kind of saw how they worked. I think a lot of us were blown away with those results. When Praxis came with relutrigine, it was a paradigm shift again to say this is not a sodium channel blocker. This is modulating persistent currents from sodium channels, and this is a completely different mechanism of action in that it's more, like Steve just showed, it's more potent, it's more selective. That for us is, it's a different medication. Yes, it works in the sodium space, but how it works is completely different.
I think that's an important distinction to make, is that we can't lump this in with eslicarbazepine or one of the other previous medications. To Doug's point is that it was very rigid for us in terms of how we think of sodium channel medications. Before there was a Dravet Syndrome Foundation, before there was dravet.org, there was a group called ICE, which was like Ion Channel Epilepsy, and their logo was just lamotrigine with an X through it. That's how we thought of this. Now we see that, well, maybe if we target, if we're more strategic with how we target these sodium channel currents, then this opens up a whole suite of options that we didn't really know existed for those patients.
I think the epileptologists are, especially those who are dealing with DEEs, are hungry and desperate for anything that shows significant efficacy like this does. I think the general neurology community, once they understand that distinction about how this is not the same as what we were talking about 15, 20 years ago, I think they'll be and especially with the easy titration for it, I think this will be easy for it to be taken up by the community.
Great. You both sort of alluded to some of the mechanistic differences between sort of sodium channel blocker, sodium channel modulator. I guess what's your level of confidence in the sort of distinct mechanism here in terms of selectivity for persistent sodium current and the potential for broad use across DEEs? Is there anything, obviously, we'll get the EMERALD study, and that'll sort of answer the question with some finality, but is there anything in sort of the clinical data that you would point to now to kind of increase that confidence?
I realize there's an irony in saying this as someone who specializes in genetic epilepsy, but over time, I've come to appreciate the mechanism of action doesn't matter as much. I've come to look more at does it work than how does it work. I was influenced very early when I had an early patient with a KCNQ2 mutation. At the time, there was a KCNQ2 blocker that was in development that we were very excited about, but the foundation was saying, "Actually, it's a sodium channel blocker that's the most effective medication." I, being a young fellow, was like, "No, no, I want the latest and greatest, and I want to give what's best, but we know it's going to take some time. Let's start the sodium channel blocker." Sure enough, worked like gangbusters, was seizure-free.
I think I've developed a healthy skepticism over the years in saying that it doesn't necessarily need to be targeted to this. You can say whatever you want about how it works. At the end of the day, it's does it work? When I was first approached about participating in this study, I was certainly intrigued by the early in vitro studies. I was intrigued by the fact that it's working across all the different models that they were seeing. It's a lot of the other factors, actually, that appealed to me, and the fact that it was once-a-day dosing, the no titration.
I'm like, "We're starting from a really beneficial point that it seems to work across all these models." I love that we're starting with a model that first makes sense and that we're doing And we haven't talked about it, but it's SCN2A gain of function. SCN2A is not just gain of function. It also has loss of function phenotype. We're really doing this intelligently and carefully at first, but then we're kind of saying, "Yeah, actually, it looks like it works across all of them." Obviously, we don't have the EMERALD data yet, but that's really where it's all going to boil down to. I don't see any red flags across the in vitro data that makes me worried that it's not going to.
Again, we see lamotrigine work in I have a few patients with Dravet syndrome where lamotrigine works, and it's a sodium channel blocker, technically, under the old definition. At the end of the day, if it works, I'll use it. I think that I'm really going to Again, from what we have so far, I'm excited by the possibility, but it'll all come down to what is efficacy data.
Yeah, I totally agree. I think the prior experience that we have, like you mentioned, lamotrigine, and we've had patients with Dravet on XCOPRI, and they have done actually very well. I like the idea of precision-based medicine. But if we get too wrapped up in the mechanism sometimes, then we lose sight of the bigger picture, which is quality of life for these patients. If it works, then it's something that we would use. But the data does look very good. I mean, and the preclinical data with different animal models has been very impressive, and it aligns with some of the previous medications that's already on the market in terms of that.
I think that my hope is that we're going to see the DE data being positive, and that we'll see signals of maybe particular syndromes that may be very good, and then hopefully, if Praxis is willing, to explore that further in terms of how much better. I think we saw that. You could see that even in the EPIDIOLEX, like the first paper from EPIDIOLEX was Devinsky's and Sullivan's IND, right? They just gave a lot of people EPIDIOLEX and saw how they did. And the numbers were not so amazing, but then when you teased out what the signals were and then look at the later studies in LGS and Dravet and TSC, those numbers were much more impressive.
I am hoping that EMERALD is not the end, it is the beginning of identifying particular epileptic encephalopathies that we see frequently in the DE population, and then hopefully target those as well.
What level of data do you need to overcome inertia for your colleagues? You are saying, if there is enough Dravet data, you would use this in Dravet. Is there a certain threshold beyond EMERALD, or is EMERALD enough? Or when we look at the data, we just know? And does seizure type matter too for sodium channel? I think, is it contraindicated for absence?
Yeah. I think Dravet is a special case, which I think it is going to take a while before people are going to be comfortable experimenting with. I think, as Eric had pointed out, when I have at the end of the line, they are on everything, I would be open to trying it, but it would certainly be lower in my algorithm. Generally speaking, yes, we tend to typically think for sodium channel modulators, more focal epilepsy, generally speaking, and generalized tonic-clonic seizures. But we also know that from lamotrigine and we know from rufinamide that we can also see with certain generalized seizures, like tonic seizures, that we can see efficacy. But to your point about your original question of what do I need to see, I think I break it down between a targeted population versus a very broad indication.
The targeted population, I am looking for clear, powerful efficacy data. This is a carefully selected, almost in some other studies, it is more like cherry-pick. This is like our dream situation. You need to see that this is really effective. And I mean, obviously meaningfully impressive. When it comes to the broad indications, I look at the LGS studies, and this is our first for DEEs, along with bexicaserin. All I need to see is statistical significance. I need to see some evidence that it is working in order for me to start introducing it. I do not think we are going to have enough of an N from these initial studies to really say we are going to start focusing on these specific subsets. It is going to be okay.
Now we have a new tool in our toolkit. Then we're going to start trying it. Then there's going to be kind of a collective, "Okay, this worked in one of my DEE syndrome patients. Now I want to try it in more of my DEE syndrome patients." We are a small community. We talk. I think that pretty quickly that it'll kind of spread from there. Most of that is not usually in the literature. This usually winds up happening kind of more through direct conversations at first, because it certainly happens at our institution where we say, "Hey, have you noticed fenfluramine for DEE? This is really impressive." Then we all just start kind of moving in that direction. I think from the EMERALD study, I'm not necessarily going to take away.
I'm just looking for statistical significance so I can start trying it. Then, for seizure types, as I kind of had hinted there. Not as excited for absence, but again, lamotrigine works, so I think that I would try it. I would have no opposition to.
Yeah, I mean, I think the bar is relatively low in terms of finding effective therapies for DEE. We don't have a lot there. Having said that, I think seizure types could be incredibly important, depending on the cases, right? If you look at the fenfluramine data for Lennox-Gastaut versus Dravet, I mean, it was not meaningful in terms of what they could do with drop seizures. Maybe they said it was meaningful for convulsive seizures, but I don't think it was so impressive. So, it'll be very helpful to know what seizure types were more effective than others. I'd like to see what that looks like. I do understand that the ends, I can't imagine them. I don't know because the data's not out, but I can't imagine the ends of any particular syndrome is going to be that high for us to glean a lot out of that.
But if we have statistical significance, I agree. I think if we have and then if we have numbers that look like what we see in other medications with heavy burden of seizures, I think that could be very promising for us. But in general, I would say that if we have strong signals for, my hope is for SCN2A, SCN8A, then we're going to have similar signals in the larger, broader population. We're still targeting the same issue in seizures, regardless of the etiology of those seizures.
Got it. Maybe just like kind of high-level thoughts on how you see sort of the progress of treating DEE and sort of the segmentation between, let's call it like a sodium channel modulator, like relutrigine, where there's certainly mechanistic rationale why it would have this sort of effect across DEEs. But we also have, and Praxis has their own efforts in here, but like the ASOs where you're actually genetically targeting mutation to sort of turn the underlying disease around. How do you kind of see the field moving, and if we had all of these at our arsenal, where would you be using each sort of program?
I think that for the foreseeable future, there will be a role for both. I think that we have some early data to support that hypothesis, that the zorevunersen data had shown that for Dravet syndrome, we're really not coming off of anti-seizure medications. We are seeing some benefits. We obviously have a lot more data coming for that. But the rest of the ASOs, I mean, time is going to tell. I think that in order for us to have a meaningful replacement of our conventional ASMs with targeted genetic therapies, it needs to be introduced much earlier than, A, we're prepared to do, at least with our current technology, and B, when there are a large number of hurdles that are going to be keeping us from introducing it early enough. Now, what do I mean by that?
For Dravet syndrome specifically, by the time we have figured out that they have Dravet syndrome, that they are refractory to their initial treatment, and going through the initial pipeline, they've already gone through status epilepticus a dozen times. We are thankfully now aggressive, and I will say some people are more aggressive than others, in that we're trying to get that under control better. But by the time that they've gotten things under control, their brains have already taken the hits of several prolonged convulsive seizures. Even if I fix the underlying genetic deficit and I control the ongoing seizures, I equate it to a football player taking repeated hits in practice. We've seen the CTE. We know that they're going to have a lasting impact even if they stop playing football at that point.
We're getting there, but our technology right now, we can't necessarily tell the difference with enough precision to say that this mutation is going to cause a severe Dravet-type phenotype. We can say it's very likely, but we don't know. Do we have the confidence enough to then initiate a genetic-based therapy to prevent the rest of that course? Dravet is one of our better understood ones, and we're not there yet. I think that for all the other ones that we are having these ASOs that are coming in, by the time that we recognize that a lot of these issues have already taken place, and I don't think while we can help, we can't fix. That's, I think, where the conventional ASMs will come in.
I just want to make sure I understand your question. You are asking, given the different MOAs, how do we decide which treatment to give first? Is that your question?
Yeah, to some extent. I mean, really just kind of like how you think the landscape evolves in terms of using ASOs where you are directly interrupting potentially the mutation versus using an ASM, and it seems clear you would use ASMs regardless, because we are not seeing cures of ASOs. But where in sort of the sequencing would you?
I would say that depending on how these treatments complement each other, I could see myself doing a buckshot approach. We should for sure try to target a gene if we can, but that should not hold us back from also trying an oral ASM. I am not sure if one necessarily has to eliminate the other. We generally like to make one change at a time, and I understand that, but the volume of seizures cannot be understated. For a lot of the subjects that I saw in the study, they were having three, five, or more seizures a day. We have families that use the clicker that you will use to see how many people walk into a stadium. That is how they count for seizures. It is brutal.
To say, "Well, we are going to try this, and we will give it a few months and then come back." Even what Steve was talking about before, about the way the study was designed, one of the reasons that sometimes we reject studies is because we are worried that the baseline period is too long, that the placebo arm is too long, and it is hard for us to recruit patients because they will say, "Well, if it is 12 weeks placebo and one month baseline, so it is going to take us more than a quarter of a year before we actually." We do not have that kind of time, and the patients do not. I think that the treatments like the ASOs, Bexi, if it comes out positive with DEEp SEA or DEEp OCEAN, and then also the EMBOLD data, I think they can all work with each other and complement each other.
I don't see a reason why we'd have to choose which one.
Doug, you kind of mentioned before that statistically significant is good enough for you to try it, and that's sort of like the clinically meaningful hurdle. I guess I would just kind of maybe not push back, but just would love your thoughts on how sort of the payer dynamic currently works and how much delta over placebo would influence how much pressure you would put to use expensive drug over sort of payer pushback.
Yeah. I'm fortunate to be in an office where we have tremendous back office support. For all of the letters of medical necessity, up until peer-to-peer, I don't have to do anything. The insurance pushback, to be quite honest, plays no role in my decision-making. I do acknowledge that if I have what I believe to be an equally effective option, an equally safe option that is cheaper, I will choose the cheaper option, generally speaking, particularly if I have a lot of experience with that drug. There is a certain amount of inertia to get over in order to try something new. But I have a number of patients that have tried everything. It's going to start with them, where I'm going to get my feet wet and see, is it working?
If I do have that experience, I will start then applying it more broadly. So yeah, the insurance piece, I would say, does not particularly impact my practice.
Doesn't really impact my practice either, but it does impact others. I would say for the folks that I know who work in academic hospitals and community hospitals, they don't always have the most amazing prior auth department. The prior auth department just may be that doctor, and that's it. So yeah, obviously, seeing something highly significant is definitely going to be easier for us. But again, I really wouldn't underestimate the voices of these families. A lot of these communities are incredibly motivated, and they come to our office informing us what they have heard and what they want to try. They are amazing advocates for their kids, and it doesn't end when they leave our office. I see that there'll be probably multiple touch points with the insurers in terms of who's advocating to try to get these medications approved.
If relutrigine was approved for broad DEEs along bexicaserin, how do you think about using those two drugs? Where would you sequence each? Is it at a point where you'd just kind of be like 50/50 where it goes, or do you have a vision for which you'd use first and which patients?
I think that the 3x a day dosing versus one time a day. Well, I have to highlight before I even get there, the efficacy data will be the primary determining factor. If bexicaserin works, apparently, I know obviously we can't say scientifically it works clearly better despite what those numbers show, but realistically, if one shows a 50% reduction and one shows a 30% reduction, I would be leaning more towards the 50% reduction, even if it is 3x a day. I think that is first and foremost the deciding factor. I will say that the proof is in the pudding. I had the opportunity to be a PI for the bexicaserin study, and I passed.
I thought that it was I could not find myself selling it to patients because you ultimately do have to sell, as Erik had said, they have to put the faith in you to say that, "Yeah, we're going to go through this blinded period where we're not going to touch the other anti-seizure medications." I couldn't get there with that specific study. I think there are obstacles to it, but again, depending on the effectiveness, if it shows efficacy at the end of the day, I'll use it.
I was a sub-I for bexicaserin, in addition to working here with EMBOLD and EMERALD. I think both could work well together. I think it really depends on the EMERALD data. I think it also depends on what the Bexi data shows. If it is going to be just a safer version of fenfluramine, then I am probably reserving it mostly for Dravet. I do not know about you. I have not been in love with fenfluramine outside of the Dravet space. My hope is that there is going to be more options that we could hit with relutrigine. I am not sure where we are going to go with bexicaserin.
I think it is going to be depending on the epilepsy syndrome type, seizure type, and then, like you said, in terms of efficacy, we spent a lot of time today talking about MOA, and there is a lot more to talk about here. I think MOA, like you said, one of my mentors, he gave a talk at AES about how does MOA really matter. Not to say that it does not for the people who designed relutrigine, but we talk about medications like vigabatrin, like tiagabine. No one even prescribes tiagabine anymore. These were GABA-specific medications. MOA could be important, but I think at the end of the day, it is going to be how well does it work.
Great. If relutrigine were to be approved in SCN2A and 8A patients, at the end of this year and is launched next year, how do you kind of think about the uptake there? What percentage of patients would use it? Is it the point where it would be like, "Oh, we just try it in everyone," or is there anything to kind of consider in terms of penetration? How does that change relative to broad DEEs?
I think I have a pretty clear answer for that one personally. I have two patients with SCN2A gain-of-function/SCN8A who were not well-controlled or were not in the study. For both of them, I am applying for expanded access for relutrigine, and both of them, it was patient-driven. Granted, I mean, obviously, I am familiar with it, and so I had mentioned it, and they were very, very interested. I think that my experience with fenfluramine, well, actually, before that even, for EPIDIOLEX in Dravet syndrome, there is the community talks. At the end of the day, whenever that first wave hits, it is going to be, what are they internally saying? For fenfluramine, there was a massive wave of support that drove adoption, but to look at it, we are still not quite using fenfluramine all that much in our Dravet patients.
For EPIDIOLEX, there already was, by the time we were doing the RCTs for fenfluramine, the community had already said EPIDIOLEX is not doing it. The enthusiasm waned very, very quickly for EPIDIOLEX in that specific population. Right now, enthusiasm is high in that community, but it ultimately will depend on, do our real-world experience match what we are seeing in the trial?
We had over 40 subjects in the EMBOLD data, in EMBOLD site. Those were not all our own patients. Those patients came from really diverse areas of the world, and not specific to our center. It was breathtaking how well people did. I mean, it was remarkable. It would be, again, these patients are typically getting started on something in the hospital setting, so I do not see it being a first-line medication, but this would be our first-line outpatient medicine for this population. It has been remarkable how well it has been both tolerated as well as how far it has driven down the seizure burden, and it has opened up their kids where they really feel like they have not interacted with these children like this before. It is high on my list.
Great. Just to kind of contextualize that in terms of the addressable market, I think at the top you sort of said about a third of patients with DEEs do not see seizure control, and those would be sort of the addressable ones. When you think about this, is that the same, or SCN2A and SCN8A patients, are two-thirds of them getting seizure control, and therefore that would not be addressable with this? Or would this potentially expand beyond?
When I was quoting the 33% not achieving seizure control, that is epilepsy overall. The DEEs, the lack of seizure control is dramatically higher, and I cannot cite a specific study, but in my population, I would estimate it is greater than 90% still have ongoing seizures.
I guess to kind of go into a little more depth on the competitive landscape and go beyond bexicaserin, I mean, you did say you are using Xcopri a lot. How do you kind of think about the sort of broad DEE targeted drugs versus companies or programs that are targeting sort of broader seizure type, like going after focal onset, generalized clonic-tonic? How do you think about kind of utilizing, with Xcopri as an example, would you try Xcopri ahead of relutrigine? Are there patients where you put relutrigine ahead of Xcopri?
Yeah, good question. I think that for Xcopri specifically, I think that the fact that it was tested in adults first and foremost, the younger they get, the more hesitancy I have in initiating it. Certainly, for most of our DEEs, they are early onset. I think that is right now one of the barriers to Xcopri, but that could change with time, of course. I think, as Eric had pointed out, if they are already on clobazam, it is very hard to tolerate Xcopri. That would be another barrier. It is quite sedating in that perspective. The way I look at it in terms of, I think that ultimately it is a marketing.
It is a way to get us to think of those medications when I have a specific. When I have a patient who has been on my first five typical medications, where I am starting to think outside of my usual armamentarium. Again, this is now not necessarily a precision medicine. We are now talking about a more diffuse, a DEE. I think rufinamide tried to do that with drop seizures, and so that very quickly came to doctors' minds. When it came to focal onset seizures, obviously that was the kind of thing for Xcopri, and then it had an efficacy signal, and so we are just kind of using it all over the place now. For fenfluramine, the GTCs. Ultimately, there is just an angle that we are going to be using. I think that historically it used to be Lennox-Gastaut, and it used to be focal onset seizures.
I think that DEE is just a rebranding of something we have already known has existed for a very long time. I don't think of Depakote as being a DEE medication. I think it is just a wonderful seizure medication, and anything that is a wonderful seizure medication I will use in DEE.
Yeah. I think that if there's a couple things. One is that we were involved in SK39 and 40, which is the two and above for Xcopri, and I think we had the largest enrollment. In those patients, they did very well, but it's a slog. It's a slog to get to therapeutic dosing. Then it was a mess if we had them on lacosamide or clobazam together. Again, if we have a medication you can start quickly, it doesn't interact with most medications, or you could predict what those interactions are going to be and you can anticipate for it by making changes proactively, and you could start quickly and stop quickly, I mean, that's pretty impressive. You don't have to say, "Oh, by the way, it's a very safe medication.
You just need to get an echocardiogram." That's not very appealing to a lot of families. I think this is going to be used well, and I think the uptake, I think, for this medication compared to some of these very effective focal onset seizure medications, being that it's easier to use, it's not so messy, it's more selective, it's more potent, I think a lot of people are going to take it up pretty quickly.
Well, great. Doug, I know you got to run, so I'll cut it off here, but really appreciate the insights. It was super helpful, guys.
Thank you.
Thank you.
All right.
Am I on? Yeah. All right. I am acutely aware now that both John and I are standing between you guys and lunch, so bear with us for another couple of sections here, but important sections as we go into the commercialization of relutrigine. Second product this morning with great data, great science, huge unmet need, but obviously a very different market as we think about our go-to-market plans and what we need to do with relutrigine compared to what I just took you through earlier this morning on Ulixa. Ultra-rare disease, as we know and we have just covered here, in a pediatric population. You have caregivers as the central decision-makers for who is going to go onto therapy here. Care is concentrated in centers of excellence, we know that, treated by specialized pediatric neurologists who we just heard from Drew this morning.
This is an activated and engaged family group that we are dealing with here within DEEs, but within SCN2A and SCN8A as well. We will distribute through a single specialty pharmacy, still in the specialty pharmacy realm, similar to Ulixa, but there will be a single specialty pharmacy supporting our launch here. With this engaged and activated set of caregivers, we will engage one-to-one with each of the families. We will build our field teams to hit those centers of excellence. We will go more broadly than that, and you will hear that from John in a few minutes. But having those centers of excellence gives us a built-in stakeholder and targets that we can go after right at launch. Then most importantly here, I think, tone matters.
We will launch with humility, and we will look to earn the trust of each of these families so that they feel comfortable giving Relu to their children. Steve covered this at a very high level in his section, but I do want to spend just a little bit more time going through what a family affected by SCN2A and SCN8A actually goes through, mainly because this is very important to how we think about the commercialization and what our go-to-market strategy looks like. As Steve mentioned, it starts at birth and does not get any easier from those first symptoms. Symptoms appear most commonly as seizure right out of the gate. Families then usually first have their experience with the ER or with their primary care physician, just given the urgency of needing to do something about the seizures with their children.
About 50% then will be seen by a neurologist within two months, and then it will take another four months before roughly half of those, 45%, will receive a genetic diagnosis. In between that visit with the neurologist and getting that genetic diagnosis, they are already being prescribed anti-seizure medicines simply because neurologists cannot wait to confirm the genetic diagnosis. Physicians start ASMs then and start to cycle through. They are really looking for anything that is going to hold and start to control the disease. 60%-70% of the patients then are concentrated at the academic centers, as I mentioned at the beginning of the slide here. That is a reachable prescriber base for us, and it will be compared to the broader DE population, the 2A/8A patients follow a much more acute and seizure-driven entry into care.
Once they do get into care, physicians, as we heard a little bit from the panel just now, they do not have a lot to work with specific to the SCN2A and SCN8A patients. Treatment is reactive to the seizure presentation. There is no defined order of therapy. We heard that. They do not know exactly where to start and how to cycle through. That is true for 2A/8A. It is true for broad DEEs as well. Physicians rely on generic ASMs in combination. The few that are on label are generally only used for what their on-label indication is, and there is nothing approved for SCN2A and SCN8A. Physicians escalate doses, add ASMs, and despite taking these multiple approaches to bring the disease under control, nearly 80% of patients are not seizure-free, even with all these treatments. The key point here is that aggressive therapy is not delivering control.
Physicians are using the tools they have, and that simply is not enough, and that opens up the opportunity for a specific targeted therapy in this population. There we go. First, let me set this slide up a little bit. This was a blinded market research with 128 DE treaters and exposing them to the EMBOLD data that Steve had covered a bit earlier. When comparing Relu to the current therapies that they have in their armamentarium, physicians rated efficacy, quality of life, and tolerability as significantly better than what they have on the market today. 98% of physicians shown the blinded profile for Relu expect to use it, and they expect to use it, about half of them, 47%, in combination with other anti-seizure medications, 41% both as monotherapy and in combination, and then about 10% as monotherapy only.
Key point here is nearly nine in 10 neurologists plan to use it alongside their existing therapy, which fits how DE is treated today. Introducing Praxis Horizons again, third time you've seen it this morning. It is important for us as our hub here, consistent with what I showed you with Ulixa. It is our Hub of the Future for relutrigine as well. Each step for Praxis Horizons is owned by Praxis or a dedicated partner. Starting on the left there, Praxis Horizons Digital Pharmacy receives the ERX through the EHR, and you heard how nice it is just to be able to pull it down in Epic, select the product, and the ERX goes through. The benefits investigation will start immediately. We'll immediately outreach to the patients.
They'll receive, or the caregiver in this case, they'll receive a text within minutes of receiving the ERX, oftentimes while they're still in the physician's office. We have an in-house care coordinator team that is going to follow then that patient's case from the prescription ERX all the way through to fulfillment and refills, and they're really handling logistics along the way, making sure the PAs are moving through quickly, the information's getting to our specialty pharmacy to dispense and refill. So they're handling all the logistics following each case along the way. We have a separate team, which is the patient education liaisons. This is an infield team, so they're really handling education, what to expect when the patient goes on to Relu. They will be visiting the patient's home, especially for that first dose of Relu.
And then our single specialty pharmacy, we have a set of access specialists as part of the team at the specialty pharmacy that'll be able to answer access questions, but also then handling the dispense and refill. All right. Again, now going back to pricing analogs here. As Marcio has previously communicated, our pricing corridor is $400,000-$600,000 per year for relutrigine. We benchmark to rare disease analogs, starting with SEPHIENCE as the most recent launch. The slide here shows the analogs run from about $415,000 up to $1.8 million per year, and a patient population of roughly 1,000- 12,000 across each of these analogs. And then similar to what we communicated from a Ulixa perspective, we will price to reflect our innovation and value to patients while limiting any restrictions from an access perspective.
Since there's been a bit of a debate around what happens to price when you get label expansion, we thought it was important to take a look at the analogs and see what the data says. So here, AMVUTTRA went from about 10,000 patients to 200,000 patients, SOLIRIS from about 5,000-8,000 up to 50,000 patients, and then BRUKINSA from 25,000 patients up to about 240,000 patients. Each of these represents exponential increase from 5x- 20x from their launch indication, and in each of these instances, price either stayed same or actually increased post the label expansion. Starting on the left here, so from a prevalence perspective, there's at least 10,000 SCN2A and 8A patients. Of those, about half, or 5,000, are diagnosed specifically with a genetic test to confirm.
And then when we look at what we see in the claims data and the genetic testing data that we are able to purchase, that identifies only about 1,900 patients out of those 5,000 or 10,000 that we see in the claims. John will tell you a little bit more about that, but our fields team has been in the field since August profiling customers. They have already profiled 100% of our tier 1 customers, and they have made significant progress into both our tier 2 and tier 3 customers. Encouragingly, they have already identified far more than the 1,900 patients that we see in the claims data.
They are already approaching what we see from a diagnosis perspective, and we will continue to have the profiling go on until we get FDA approval here, raising that number even more and giving us, I think, full visibility into where each of those patients are from the 5,000 diagnosed perspective. Contrast that with what you normally see in a rare disease launch, where you are really hunting for patients right out of the gate, trying to find even the patients that you see in the claims data and chasing those for the first couple of years. We will know right out of the gate where all 5,000 of those patients are. Then looking a little further, thinking about the broad DEE population.
Using epidemiology-based estimate based on published information and survival data that is in the public domain, broad DEE expands us out about 30-fold up to more than 300,000 patients on the broad DEE side of things. Fewer than 20% of these have a genetic diagnosis, so many have poorly defined disease. You heard from Steve as we think about the EMERALD trial, more than 50 etiologies here. A broad label would let patients without a confirmed genetic diagnosis have a new important option within the broad DEE population. Getting back to numbers here a little bit. Starting with just 2A/8A alone, assuming a 25% market share of the 10,000 estimated population that I shared a couple of slides ago, that equals $1 billion in gross sales just using the $400,000 WAC that is at the low end of the range that we have talked about.
Looking then at the broad DEE population, just a 3.3% penetration into the more than 300,000 patients here, or about 10,000 patients, is about $4 billion in sales here. Combined between 2A/8A and the broad DEE population, in this example, gives us about $5 billion. The number itself is not the important takeaway here. What is important is that represents 4% share of the broad DEE market to drive $5 billion in sales. I will go ahead and close out here my section, then I will bring up John. Two assets, two very different go-to-market models, a mass market launch focused on patient activation, access, and titration support for Ulixa, and a rare disease, high-touch white glove model for RELU. In both cases, we have invested early in supply, our hub, and full launch resources that will be ready to go on day one.
I will bring John up to talk a little bit more about this exciting opportunity.
All right. Thank you again, Erik. I am equally as excited to talk about this 2A/8A population, and how we are going to advance relutrigine in the market for these very underserved populations. We have really spent the time and have a very deep understanding of where the SCN2A and SCN8A patients are, and we will have our teams focused in these areas at the very beginning of launch. If you look at the volume that is represented on the map, you will see the clusters of where the patients are within the medical centers, and we have done the mapping with the ACOs. These are where diagnosed 2A/8A patients are, and then you will see the shading by state of where the prevalence really is.
A simple way to think about it is the top 30 healthcare organizations cover 31% of the 2A/8A patients, and if you go deeper, the 200 ACOs cover 65% of where these DEE patients will be. Also later, obviously, there is foreshadowing where broad DEE, because there is a direct correlation between the centers with 2A/8A and broad DEE. It is one thing to plan for success, right, with any launch, but you actually have to do the meaningful work to accelerate and have the momentum at the very beginning. We talked about the 200 ACOs. As of two weeks ago, our team has already profiled over 400 of these accounts, and we continue to profile these accounts. To Erik's point, we know exactly where these patients are, and we will be focused on those areas at the very beginning of launch.
Then if we go a little bit further in understanding the prescribing behaviors by pediatric neurologists, it is very straightforward. 50% of these ASMs are actually written by pediatric neurologists, and you see the breakdown here, 19% by pediatricians. 75% of the written ASM claims come from these pediatric neurologists as well. That is DIACOMIT, EPIDIOLEX, and FINTEPLA, right? It is really, really clear this is where we need to spend our time. When you think about the dedicated team that Erik kind of highlighted earlier, we have right-sized the sales organization for not only what the opportunity is today, but we can shift our focus as accounts come online, they are comfortable with the profile, comfortable with how to access the drug.
We move that effort further down to make sure all of them are covered. This causes for us to not have disruption later in the launch where we are having to expand the team. We are really comfortable with the size on the 2A/8A side. Patient services is a very experienced team. They will be working with these families and caregivers to make sure that the transition to relutrigine goes very, very smoothly. Then we have an amazing medical affairs team. They will be working directly with the KOLs on scientific exchange on relutrigine's profile as a precision sodium channel modulator, including the reviews of our clinical trials and safety. We have dialed all this up, very compliant collaboration. I said this earlier in talking about ulixacaltamide. We leverage the agile model where we are meeting daily to make sure impediments, insights are being shared, and we are adjusting along the way.
We are already working in that model. We are very, very excited about that. This really speaks to the fact that we have the foundation that is already built for us to expand into broad DEE. As of today, our rare epilepsy team has profiled 100% of the top 10 accounts for every single territory. We have reached all of our tier 1 and tier 2 HCPs, which is really, really important. Now, we are already about halfway through that third category, which is very, very broad. We are pleased with the progress there. What has this allowed us to understand? One, again, we know where the 2A/8A patients are. These are confirmed, as Erik said, we now know that there are actually more than what the claims data has shown. It is very, very encouraging.
We also understand the genetic testing workflows, and how that information is being moved through those offices. We understand the scheduling for each one of those offices. The key takeaway here is that we know these accounts intimately, and we will know that at the very beginning of launch of where we are going to be spending our time. Then, when you think about the payer landscape, as a genetic precision medicine and the fact that we are in a very, very high unmet need area, the payer mix is going to be about 45% Medicaid and 50% commercial. We expect PA criteria. However, the prior use of ASMs will meet most of what is required. Then the payer strategy is going to rest on three key points. There is a high unmet need for relutrigine.
It is the only targeted therapy against the limited efficacy of ASMs, which supports very, very favorable placement. Patients will arrive pre-qualified for that PA criteria because of the early onset, that leads to earlier diagnosis, specialist confirmation, and of course, prior use with ASMs. All of the previous analogs really do support that we will have earlier access through managed care. That is really, really encouraging. As I move to close this segment and really an amazing morning, we have these two products that we are going to bring to market, and we are going to deliver with more focus and precision than any other drug launch in history. We truly believe that because of the work that we have put in. We are planning for success, and we are going to be intentional about every move we make in the market, and we absolutely plan on over-delivering.
With that, we have talked a lot about launch. We are going to drop the A, and we are going to move to lunch. Now, we will move on to our lunch. Thank you all.
The program will resume in 10 minutes. 10 minutes. Please make your way to your seats. Thank you. The program will resume shortly. Please make your way to your seats. The program will resume shortly.
I think we're going to restart. I hope the morning was productive for everyone. I really appreciate everyone who came in and spoke. The first part on the first slides, when I presented, was to give some confidence about the markets, how much we know about it, and really how successful we are. As John said at the end of his talk, is really overperforming here, and overperforming here means a lot of things for us. Financial, for sure, but the best possible access, the easiest possible way for these drugs to get in, remove the administrative burden from all the physicians, making the life of the patients easier, and you can go on and on about that. I'm sure you are more convinced than ever that we know what we are doing there. Going to switch now to what is next.
As you might recall, this expanding a fair bit, right, from what we had a couple hours ago in our website and our SEC disclosures. First thing is I have to apologize. We're going to have to spend a lot of time with Steve. Which I do, and I know it's pretty hard. The good news about that is that he's definitely a lot smarter than most of us, me for sure, and is going to be able to give us a very deep understanding on why we're so convinced about most of this. Then right after, we're going to have a Q&A. The Q&A- Maybe I'm going to do the intro now, because it's going to be easier. Whatever you want to talk about from the conversations during the day, take your notes, ask. There is no specific thematic or area.
We just want to have a very fluid discussion about what the questions are. We're going to have a bunch of microphones, can go around, and get the questions. If you have people who are not here but are connected, they want to send you questions, they're going to ask us, please, by all means, do that. But enjoy Dr. Petrou for the next hour or so.
Thanks, Marcio. On that point, and the fact that it's after lunch and that can induce sleep, I used to lecture a lot. On one occasion, when I learned not to interact with the crowd anymore, there's this guy fell asleep during my lecture. I went to the guy next to him and said, "Can you wake him up?" He said to me, he goes, "You put him asleep, you wake him up." I hope that doesn't happen today. All right. As Marcio said, we're going to really do a dive into our platform, into our whole pipeline, and the platforms that support it. First, I'm going to talk about Cerebrum, which is our small molecule platform, and then I'll give a quick summary of our Solidus platform for the antisense oligos.
We move to Cerebrum, and we want to talk about our clinical programs, but we want to talk about the platform that makes that broader pipeline possible. Cerebrum combines our understanding of neuronal physiology, computational design, experimental pharmacology, and genetics to really identify molecules that act on dysfunctional excitability. The objectives is not just to produce molecules for the sake of making them, but it really is to create this repeatable engine that moves from an electrical mechanism and a well-defined disease mechanism to a clinically differentiated orally available medicines. The first program within Cerebrum is our T-type calcium channel pipeline. We're turning that, and we're starting to call that a franchise, and we'll talk about why later. Ulixacaltamide has really set the foundation and provided the clinical evidence for the mechanism of T-type channels in essential tremor.
We're now asking the question, how far can that biology take us? Can we modify molecules and the way they're delivered to broaden the reach of T-type calcium channels? Our ambitions obviously extend well beyond essential tremor, and we're pushing three complementary strategies to try and capture that opportunity. Maybe first and most importantly, we really want to maximize the value of ulixacaltamide itself. We invested heavily into that molecule, established the clinical efficiency. We now have an opportunity to leverage all that prior investment and knowledge into a much larger indication space, including Parkinson's disease, restless legs syndrome, autism spectrum disorder, where we believe the underlying biology provides a compelling rationale. Beyond that, we're developing next-generation molecules with different calcium channel types, subtype selectivity, and state-dependent properties, allowing us to tailor the pharmacology to different diseases.
Finally, we're exploring new delivery technologies, including our transdermal patch that could provide more consistent exposure, greater convenience, and potentially improved tolerability. It's much more than a single drug and a single indication. We're trying to build this entire therapeutic franchise around T-type calcium channel biology. Ulixacaltamide's the foundation, but we think there's an opportunity to unlock substantial additional value and human impact from what we've already developed. Let's start with the new frontier, new indications. We have a medicine with compelling phase III evidence, and we see rationale to investigate it further. The strength of that rationale is not identical across each of these conditions. We are developing it according to the biological evidence, clinical feasibility, and the scale of unmet need.
It sort of recapitulates the point Marcio made, is that we want to apply the discipline of how we act in a continuous basis on Praxis. We're not going to lose sight of that discipline just because we're looking broader. We have to keep the focus on that at all times. I think if you look at this slide, you can see essential tremor, and then you can see these other indications. It's striking to me, and I know Marcio doesn't like me saying this, but I really see this opportunity in T-type calcium channels as a GLP-1 moment for the brain. Essential tremor affects approximately 9 million Americans from the estimate used here. We're looking at conditions that can add many millions more potential patients.
The prevalence estimates sort of show the estimated disease burden, but the opportunity here is that a common physiological target might be relevant across several large, inadequately treated neurological populations, and likely even more that are not currently under active consideration. This could be a really huge space. Each indication has its own unique treatment gap. In Parkinson's disease, tremor can remain problematic despite dopaminergic treatment. In restless legs, existing options are limited by augmentation or tolerability issues. In autisms, approved medicines marginally address irritability, but not the broader core symptom domains. A non-dopaminergic circuit-directed treatment really could offer something genuinely differentiated. The question really is how the biological rationale transfers into meaningful clinical benefit in each of these indications. Maybe to understand that a little bit, let's just go a little bit deeper on what the biology of T-type calcium channels, and what they contribute to.
The thalamus is sort of the poster child for T-type calcium channels. It's the domain where it was really first revealed around burst firing and sleep. Sleep spindles are generated by an exquisite interaction between calcium channels and others in the thalamus, and that, of course, has given rise to other conditions, disorders that relate on that. But the thalamus is an important relay. These T-type channels, they contribute to a mode that switches the thalamus between this rhythmic activity to this burst firing that's exquisitely dependent on T-type channels. When the thalamus is bursting, that has physiological roles, but abnormal rhythmic activity disrupts the ability for the thalamus to relay signals to other parts of the brain. It's called thalamic gating, and it's an incredibly important process for so many things.
The thalamus is the site at which all sensory vision, olfaction, audition, everything comes through the thalamus, and then it's directed to the motor cortex, the sensory cortex, the visual cortex. It's a really important part. The lateral geniculate nucleus is so critical for vision, for instance. So it is the traffic cop or the relay for that, and it can be its ability. That's why it's important in sleep, because you couldn't sleep if you couldn't turn all that off. That's why sleep spindles, and that's why the bursting mode that the thalamus enters when you sleep, and you can see it so easily in the EEGs, is to quieten the world so you can shut your brain off and recover your neurochemistry. Very important.
Therefore, when that modulation is abnormal in any way, it becomes an incredibly important site for modulation, and that's why there's broader We don't know where the boundaries really are, given the thalamus' central role in the brain, what conditions in the indication space it might really represent. So for ulixacaltamide, it's not just a single thalamus story. T-type channels are found in the thalamus, of course, the thalamic reticular nucleus, and connected motor and sensory structures. Ulixacaltamide, as we know, inhibits the CaV3 channel family. Different potency across the different subtypes, but it gives us access to several nodes in this important circuit. Our model is that we can dampen excessive rhythmic bursting while allowing useful relay signaling to occur unabated. But here, you look at the broader logic across all the conditions. ET, associated with abnormal cerebellothalamocortical oscillations.
PD tremor also recruits that circuit, while its other motor signs involve basal ganglia thalamic pathways. RLS brings spinal and sensorimotor pathways into the picture, and as we know, it's also got an overlay with sleep when a lot of the symptoms really emerge. Autism implicates sensory thalamic and reticular circuits in some mechanistic models. They're not the same disease, but they do share a major contribution of T-type-dependent network activity and this commonality of thalamic circuit. The point of this comparison is that maybe not one exactly the same molecule will necessarily treat every manifestation of all four disorders, but it's likely to have some impact on many aspects of each of those.
It's the same ion channel mechanism that sits in several circuits where aberrant bursting might occur, gives us a coherent experimental paradigm, tests the defined clinical phenotype in each condition, and asks whether the signal is consistent with the proposed circuit mechanism. Let's have a look in a little bit more detail at each of these indications in turn. PD is the closest, really, probably to ET, in terms of a biological extension. Tremor involves, as I talked about, the CTC network, overlaps with the pathway implicated in ET, and the basal ganglia circuits contribute to the broader motor dysfunction that we see in PD, which is the dystonia and the other behaviors. So both contain nodes with T-type channels. That creates a plausible non-dopaminergic approach to PD tremor, particularly when the tremor is incompletely controlled by levodopa.
We don't know yet how this might extend into other aspects of PD, including some of the dystonias, and we're actively debating that and considering that it could be broader than we think. But we do view that, because that strong overlap with ET, and the fact that we know how to measure tremor so well, that we view that as probably the most directly de-risked of the extension studies, even though obviously the clinical efficacy still needs to be demonstrated. In restless legs, presents slightly different challenge. Symptoms reflect abnormal sensory and motor processing, evidence implicating spinal excitability, and dopaminergic regulation as well. T-type channels, again, are present in the relevant pathways, providing a mechanistic reason to investigate their modulation. Could create a non-dopaminergic treatment option, avoiding that dopamine agonist augmentation, which is a real killer for RLS.
But compared with PD, the link is a bit more indirect. Far fewer preclinical studies in RLS. There isn't a great model of that. We know that clinical studies can be complicated by placebo rate. So we regard it with a lot more clinical risk than we would the PD study. In autism, peers looks very biologically distinct when you think about it. The others are clear movement disorder problems. There's published and our own internal data that have really generated a good body of preclinical conviction as to why it might be impacted again in this way. As I said, sensory gating and motor gating happen in the same thalamic area. So, whether you're controlling the way a sense is interpreted and cognitively dealt with versus a movement, as far as the thalamus is concerned, it's just a different relay.
It doesn't necessarily know that that's motor and that's sensory. It's just doing its job, sending signals where they are, and it's the T-type channels again. T-type dependence in the thalamus is implicated a lot in sensory gating. There is a paper that came out, not by us, by an independent academic group, that specifically investigated the role of ulixacaltamide at the neuronal, the RT network level, and behavioral levels in a mouse model of autism, where this proposal that it actually restored numerous behaviors in that mouse. They provided, like I said, the circuit level and the neuronal level rationale based on T-type channel inhibition as to why that would be the case. That's a very strong preclinical package, but the distribution of the T-type channels and the broader way that the thalamus operates, it's all self-consistent.
So, maybe want to spend a moment on how we're thinking about the risk-reward across these opportunities, because it's an important part of our strategy. It's an important part of our efficient use of capital and our discipline that Marcio reminds us of every day. We're now in a very fortunate position. We've built a strong clinical development organization, increasingly validated therapeutic mechanism. We have the financial resources to pursue opportunities that might have previously been beyond our reach. PD is probably our lowest risk, as I mentioned. Overlap with ET, encouraging preclinical evidence, leverage much that we've learned clinically, operationally with ulixacaltamide. Restless legs, I think it's a larger opportunity in terms of patient numbers, a massive clinical need, greater uncertainty around the biology and how we would clinically translate. Autism spectrum disorder, maybe quite intriguing as an opportunity.
We have compelling mechanistic and preclinical evidence, independent academic findings that we've reproduced. We also recognize the challenges translating those findings in that area to meaningful clinical outcomes. So, we consider that medium, sort of high to risk opportunity. We're not just expanding because we have capital to spend. We're expanding because we believe we have differentiated science capabilities to execute an opportunity where the potential return justifies the risk. Coupled to that, we have our second front, which is next-generation molecules. We talked about indication expanse, and this is a very related and equally important area. It's chemical. Can we build molecules that retain useful effects of ulixacaltamide while changing subunit engagement, state dependence, and drug properties? T-type channels are not a single homogenous target.
Three major CaV3 isoforms, relative contribution differs across different circuits in the brain, and we believe those differences create a meaningful opportunity for product differentiation. So, our program really is pursuing both broadening the pan-CaV3, so Ulixa is a pan-CaV3 inhibitor. It acts across all of the three CaV3s pretty much equally, a little bit of difference. Thinking about what are the subtle changes that might be important in that as we look at the different molecules that, like ulixacaltamide, that have a similar but slightly different footprint, but don't stray too much from that sort of pharmacophore space. Two molecules, the plant enter first in human studies in the first half of 2027. The ambition is to build a family of compounds that can be matched to the right patient and the specific indication. This is how some of our next-generation CaV3 profiles differ from ulixacaltamide.
You can see ulixacaltamide on the left, and you can see one of our other molecules within our PRAX-50 program, how it looks. Two things there. It has less spread amongst the subunits, and you can see between the solid and the open circle, that is the state-dependent and tonic block of the channel interaction. Those two are very similar to what we talked about in the sodium channel space, where we highly desired state dependence. We are not sure that is the case for T-type calcium channel modulation and inhibition. Here, we can dial that up and down in our program. We know that some earlier competitor products had a state-dependent molecule in this space, and the clinical results were not as strong.
We understand there could be other reasons that can happen, but it also is a piece of evidence that might make more sense as we start to understand how important not just the fact that you are a calcium channel inhibitor, but the manner in which you do that, in the same way it is for the sodium channels. Exquisitely important, easy to overlook because it sounds too complicated to deal with, but we have seen so many cases, human biology is complicated, and the molecules that we need to get predictable effects have to take that into account, and we think this is an important step to do it. The key is to do it efficiently and rapidly so we can move the programs forward. We do not know which pattern is automatically better. It is not clear, and that evidence is not with us just yet.
The important point is we can engineer distinctive pharmacological profiles and then test whether those differences translate into true clinical advantages. The third front is delivery technology, and this is an important opportunity we are particularly excited about. Oral Ulixa is the foundation of our essential tremor program, and that is not going to change. But we recognize that patients have different needs. A single approach to drug delivery may not be optimal for everyone. So through our collaboration with Remagine Labs, we are exploring an electronically controlled transdermal patch that could provide sustained adjustable drug delivery over multiple days. It has many potential advantages. It could eliminate the need for daily tablets, provide smoother and more consistent drug exposure, and potentially allow us to manage tolerability through greater control of delivery profile.
So, we are dealing with a population where the simple act of handling tablets or opening a medication bottle itself can be challenging. But the important point is we are not developing the patch to replace oral ulixacaltamide. We are developing it to complement the oral medicine. The goal is to give physicians and patients more choice, potentially reaching people who might otherwise struggle with or choose not to take a daily oral treatment. So this is a way to expand the population we can serve with ulixacaltamide while extracting more value from a molecule whose therapeutic potential we have already established. I will just take you a little bit through the technology of that. It uses a programmable electrical current waveform to control movement of ulixacaltamide through the skin. The patch is designed to hold approximately a week's supply.
The delivery rate can be controlled electronically and adjusted as needed, creating a potential for individual dosing by physicians without requiring the patient to change tablets or remember a daily dose. Clinical value could be substantial for patients with impaired dexterity or those who need tailored dosing. We plan to take it to clinical evaluation in 2027. I guess the first question is, does the data support the claim? Can we deliver enough ulixacaltamide through the skin to achieve therapeutic exposure? Here, the data is very encouraging. We've got three versions of the electrode here. You can see V1, V2, and V3. Probably the first thing to anchor on is on the very left of that drug flux bar chart, is V1 passive. This is essentially the formulation with ulixacaltamide on the skin. It doesn't get in passively. You need electrical current.
We found that out very soon in the study of this. We subsequently went on to develop additional generations. Each of those is an electrode technology, a progressive change, developed in collaboration with Remagine Labs. It incorporates design improvements in increasing efficiency of drug movement across the skin. You can see drug flux, transport factor. These are really important things that you optimize against, configuration of the electrode. All these things matter in moving, and you can see that progress has been quite remarkable. This collaboration didn't begin that long ago. As we moved from V1 to V2, we achieved about a 2.5-fold increase in drug flux. With our latest V3 technology, we doubled that again. That's about a five-fold improvement in drug delivery from our first-generation electrode.
Now, getting to the level where we're seeing substantial enough improvements in efficiency, meaning we're getting better and better at being able to move ulixa across the skin. These are all in vitro experiments using porcine skin. We're moving to the next level there to get better validation. But when we incorporate these results into our PK data that we know for ulixacaltamide, we support the feasibility of a therapeutic exposure. Let me show you that here. That's used the data we knew about the flux now, so we know how much can be delivered. We know about, obviously, a lot about the pharmacokinetics of ulixacaltamide. So we modeled the exposure profile we'd expect to see with drug entering the skin at the rate that we can do it with the current patch technology.
We show here, in comparison to someone who doses at day zero for the first time, and you can see the dose escalation and the PK stabilizing, versus a patient who, in simulation, would have had the patch turned on. We can achieve, with our current flux levels, a PK that sits pretty much in the middle of the range of the exposures provided by oral ulixacaltamide. Really encouraging here. Obviously, our clinical pharmacokinetic study is going to characterize this in a real-world setting. The title of this slide is the strategy in a sentence. I won't say who wrote it. Building the leading T-type calcium channel franchise with a timeline to the next key clinical milestones. There are three words there that I think that carry that argument: leading, building, and milestone. Leading, which I think we've earned.
We started with ulixacaltamide, which really designed around our understanding of T-type channel. We've now demonstrated efficacy through two phase IIIs. Building. Building is a single drug as a product, while a franchise is what you have when one piece of biology keeps producing products. A milestone, because a franchise is judged by the milestones it reaches, not by its ambition. It was actually a really good title, Marcio. He always changes my titles. What if ET is just the beginning? Readouts in Parkinson's disease, restless legs, autism arriving between 2028 and 2030. Next-generation molecules, first-in-human data for PRAX-50, our pan-CaV molecule in 2027. PRAX-51, our CaV3.x selective around the turn of 2028 and into 2029. Better delivery, bioequivalence data around the end of 2027. These windows are our ambition, built on historical studies in each indication. They're not just ideas on a whiteboard.
Each is a specific data-generating event, with the first data to arrive in 2027. Each study will inform future studies and help us interpret all data that we've seen. Each one tests something different. A new indication tests where the biology extends. A new molecule tests where we can do better. The patch tests whether we can reach more patients with the molecule that we have. This is what makes it a franchise rather than a wish list. I'm particularly excited that we're building all of this on a common biological foundation. We spent years and years understanding that biological foundation. We've successfully translated. I think we now have the right to think more hardly about how far this can go. You remember I mentioned that I compared this opportunity to the GLP-1 moment and mentioned that Marcio wasn't particularly fond of that sort of grandiose comparison.
Marcio, I'm going to double down. Having walked everyone in the room through it, I'm afraid we're going to have to double down on that concept, and we can duke it out in the executive meetings. I think what made GLP-1 so extraordinary wasn't that it was just simply a success in one disease. It was a realization that a single therapeutic mechanism can have profound implications across multiple major diseases. That's a possibility we see with T-type calcium channel inhibition. We still have important hypotheses to test, and I wouldn't suggest that every indication's going to succeed, but even if a fraction of those opportunities translate clinically, the implications for patients and Praxis could be extraordinary. I think it's a well-founded ambition, and it's something that's going to drive our focus and our relentless desire to execute and advance.
With that, I'm going to switch away from the T-type program and talk about our epilepsy pipeline and how it relates to Cerebrum. We have another opportunity around KCNT1 epilepsies. That's a genetically defined disorder, exceptionally severe phenotype, and clear molecular target. It's a good example of how the same platform discipline can be applied beyond sodium and T-type calcium channels. You can see here, KCNT1 epilepsies are severe. Gain of function in the channel produce devastating early life epilepsy, including epilepsy of infancy with migrating focal seizures, as well as child onset sleep-related hypermotor epilepsy. In the infant onset group, seizures begin very early and are frequently daily and associated, as you can see here, with substantial mortality, median age of three years.
That's a combination of a defined genetic driver, a major unmet need, makes the target compelling. We at Praxis were amongst the first to discover this and to understand the importance of this target. It's a big historical part of the company as well. Where do we stand? PRAX-206 is our potent, selective, and well-tolerated molecule. It's orally available. It's a selective KCNT1 inhibitor designed to act on these gain-of-function mutations. You can see here in three studies done in mouse models, we see reductions in spontaneous seizures, and also in acute seizures, all very well disrupted by PRAX-206. Importantly, in the middle, we see a non-seizure domain. Animals that bear this gain-of-function mutation in KCNT1 have very disrupted cognitive and home cage performance, including the fact that they can't build nests. Funnily enough, when I first saw this, I hadn't even thought about mouse nesting.
These mice, we always give them Kimwipes. We'd give them Kimwipes, and these mice used to leave them perfectly flat and alone. A wild-type mouse would take them and bunch them up in the corner. I thought, "Wow, this is interesting. These mice are neat." It turned out that they couldn't build a nest and do the home behavior. That's a really complex cognitive behavior. The animal's got to recognize the materials around it's got to think, and it's got to unlock the innate knowledge to build a nest. You give them the PRAX-206, two or three days later, they're building the nest. You take them off, and that behavior goes away. It's like a switch. It's an incredible behavior, and it tells us a lot about the potential, because this field barely knows what this channel does.
We know that it causes a disease when it's mutated, but its normal physiology is really very difficult to describe. It actually belongs to a family of channels that's overexpressed in the electrical organ of the eel, and that's why certain eels can produce shocks. That's one way biology's used it. We're not really 100% certain. We do know when you block a mutation either with this or with an antisense oligo, and we've published a preclinical study on that for proof of concept of this, you get remarkable effects. So, we're going to couple that with our pharmacology and our preclinical tolerability packages. We're preparing for first-in-human development in 2027, and where we'll study exposure, safety, and target engagement become next critical steps for this program. Beyond that, we've got pain as our next major application of our ion channel platform.
Unlike our genetically defined epilepsy programs, pain spans a very large and heterogeneous populations. What links it to the rest of our work is that the translation of pain signal and the transmission, so the detection and transmission depends on neuronal excitability. Sodium channels are central to that process. You can't have pain without sodium channels. The field has known that for a long time, but it's taken a lot of time to be able to tackle that therapeutically. We know in dental work, obviously lidocaine works phenomenally in oral pain. That's telling at the site where you could detect pain, you're stopping that transmission from occurring. A lot of Americans are affected by pain. Patients frequently cycle through medicines that do not provide any satisfactory relief or have significant tolerability and abuse liabilities.
The clinical needs extend from acute postoperative pain to neuropathic and chronic musculoskeletal conditions. We are not claiming that all of these patients are going to be addressable by one drug for the reasons that I have been arguing for the last half hour. The point is that even a focused indication can represent a meaningful opportunity if we bring a differentiated non-opioid mechanism with reliable efficacy. Pain signaling not dependent on just one sodium channel isoform. The field has been talking about isoform-specific molecules for a long time. We have even some, and I will talk about one, that has been marketed in that capacity. But clearly, peripheral nerves use NaV1.7 and 1.8 to initiate and transmit signals. Central pathways, which a lot of, when the current drug does not even get into the brain, include 1.2 and 1.6 channels that we know about in epilepsy.
The optimal target profile may therefore differ by pain indication and require a balanced approach to how you engage with sodium channels. The more we understand about the compartments and the pain, and then engineering that pharmacology accordingly, the better we can tackle this problem. We are not placing a single bet on pain, developing different sodium channel profiles in parallel, from a broader here pan-NaV activity to a greater NaV1.1 bias, not formal selectivity. That is important distinction. We use a, and I will talk about that in a sec, an indication-specific preclinical framework called PAC-Pain. Some of you may have heard about our PAC-Epilepsy, but now we have got PAC-Pain. That helps us select the most promising molecules. It becomes a more objective process. It is not just the favorite pain model that a CRO or a lab is running, tries to really look at objective evidence and uses that.
And we can connect the chemistry, the mechanism, the translational evidence before committing to trials, and use that discipline to try and increase the probability of success in a sort of information, data-driven way. This is the framework developed by the same team at Praxis who did the epilepsy framework. We know that preclinical models have got a terrible reputation and produce a lot of disappointing translation. As you can see here, a huge number of different models have been used in pain. We examined how a panel of models aligns with clinical results from 58 approved pain medicines, and we used that retrospective information to construct cascades for individual indications. We have a tolerability gate in that cascade. Through this cascade, we can say, for neuropathic pain, this model worked in every single study where we got an approval for neuropathic pain.
That should be an important stage gate. Can we cross that gate? And then the additional filters there of additional models provide further restriction, and we think produce the stress test, the molecule, so that we can really understand and increase its likelihood based on the information we have got. This is a continually living document. We will be updating it as new studies emerge, et cetera. But we think it is a much more disciplined way versus, "Oh, well, we have been running the formalin test and this test forever, and we are always going to use it and roll the dice." I think this is an important step. Suzetrigine, approved in 2025 last year, really important proof point for the field. It is selectively tar- You can see here, it has got a massive separation between the subunits 1.2, 1.6, and then 1.7 versus 1.8 that it is selective for.
They demonstrated that this mechanism can produce an approvable non-opioid medicine for moderate to severe acute pain. We view that as a great validation of the target class, not a validation of every sodium channel inhibitor, and certainly not a validation that there isn't any more room for improvement in this space. Our opportunity is to build on this foundation, different isoforms, use our functional state profiles that we understand so exquisitely, use that with our deeper knowledge of pain transmission. We know we got this huge literature on how pain signals transmit. Pain, in some level, you can almost think of it as epilepsy of the sensory neural system, and from that, you often do get crossing over from epilepsy drugs into pain, because many of the elements are shared. PRAX-215 is our balanced NaV state selectivity profiles.
It's a broader sodium channel approach, already in phase I, which we haven't declared openly before. It's got balanced potency across 1.2- 1.8. The design intended to preferentially affect hyperactive states, as we've talked about. The hypothesis is that engagement across peripheral and central pathways may be useful for pain types that involve more than one site of signal generation. Preclinical data support advancement. The phase I program helped define the exposure, tolerability, window within that profile can be used. We'll talk more and more about that as data emerges. PRAX-110 is our 1.8 biased approach, and you can see here what we mean by bias. We're not doing the 10,000 to one selectivity that Vertex did. We're taking a different approach from our other. We're retaining activity at the other pain-relevant channels. We think that's important, and with retaining our functional state selectivity.
What you can see here, the 1.8 selectivity here is about 28-fold greater than 215. Pharmacologically, that's a lot. You need 10,000 when you don't want to have one molecule binding in any of the other channels. We believe we don't want that. Our hypothesis is we don't want to go to that extreme. We can fold in this bias. We can then run them through our PAC Pain framework, and we can start to benchmark them against those and really build a deeper understanding of where we can take this. It'll be a differentiated hypothesis and a differentiated profile of molecules as well. For this, we're targeting an IND submission in 2027. This is where our key milestones are going to start to occur. We have two different, as I said, two differentiated programs on a staggered schedule.
215 is already in phase I, with further and acute and chronic pain studies planned. 110, expected to enter clinical development after its 2027 IND, with its own proof of concept. PAC Pain will guide where each molecule is tested. It's not just there to enter a large market, but to build an evidence-led pain franchise that can generate multiple clinical readouts. Finally, I want to turn to our Solidus, our antisense oligonucleotide program. This takes the principle of precision medicine a step further, where we can identify the causal genetic mechanism and often design an RNA level intervention, that changes the amount or processing of the relevant gene product. A little bit of that was discussed at the KOL, DEE KOL discussion earlier, and that opportunity is to make that process faster, more repeatable.
I think that is key to innovate the platform here to unlock more value and progress in the ASO space. The technology is very old. Patents are expiring, and I think the patents expired when only one program had been approved. There needs to be a way to accelerate this approach and de-risk it and bring it to the patients that sorely need some alternative. There is that option, as we discussed, that things like relutrigine could be adjunctive to a lot of these other medicines as well. We see there is great opportunity here for our patients. We have got one anchor in elsunersen here now in registrational development for SCN2A gain-of-function. Behind it are a bunch of other programs that I will talk about. What they have is a shared discipline of how we are going to do that, as I talked about.
elsunersen is a great example of the logic of this rare disease approach with antisense oligos. In SCN2A early-onset DEE, excessive 1.2 activity contributes to severe early-onset seizures and developmental delay. elsunersen is an RNase H1 active antisense oligo designed to lower SCN2A messenger RNA, thereby reduce the amount of pathological NaV1.2 current. It is given intrathecally every four weeks. Rather than modulating a downstream circuit, this approach is designed to address the causal molecular abnormality directly. In EMBRAVE Part A, we saw a 77% placebo-adjusted reduction in monthly motor seizure frequency at 24 weeks, with a P-value of 0.015. Five of seven patients met the 50% responder threshold. Four experienced a period of at least 28 days free of motor seizures, and broader functional improvements were reported. No drug-related SAEs or neuroinflammation signals were observed in the data so far.
Very encouraging in a small, genetically-selected population, and it supported a breakthrough designation. We have now moved on to EMBRAVE3, which is our pivotal single-arm study following FDA alignment on the removal of the sham control. Primary endpoint is median percent change in monthly motor seizure frequency after 24 weeks of intrathecal treatment. Plan includes approximately 30 children aged two to 18, with additional younger cohorts included in the study, largely addressing some of the concerns that Dr. Smith was talking about. How do we move earlier and earlier into these cohorts where we do not know the levels of benefit that might arise through earlier intervention? We expect a 2027 top-line readout and a potential NDA filing. The focus is to generate clear, interpretable FSE signals and a safety data set in these populations with very, very limited alternatives. Beyond elsunersen, you can see here six other targets.
Some programs seek to lower a harmful gene product, as in the PCDH19 or allele-specific KCNQ2. Others address haploinsufficiency or loss of function by increasing expression. Different diseases require different RNA control strategies. The unifying principle is that the direction of the genetic defect tells us which molecular intervention is appropriate. As I mentioned before, we need to make this process more efficient and more rapid. How can we use AI to transform the way we discover and optimize? Traditionally, the discovery has been straight through screening. You design large numbers of sequence, throw them through the cell lines, look at expression changes, and develop in the same way you would have done traditionally, really. Our goal is to try and use a learning system where every experiment makes the next round of discovery smarter.
This is a pilot that shows a little bit of how that is going to work. We used experimentally measured ASO activity that we had in our databases to train models that predict which sequence features drive upregulation. We trained it with that, and then we had a bunch of data that we knew the data for, a bunch of ASO sequences, but we had not used it to train the model. When we threw that data at the model, we got an 80% concordance under our ROC curve. That is telling us that that is a very high level of specificity and selectivity for these molecules.
Our first foray into this space has been very encouraging, and the more and more ASO data we can throw into this, the more and more we are going to be able to use that as a basis of narrowing the set of molecules we need to screen, and to do the same thing in the toxicology space so that we can more rapidly get to effective molecules, and then couple that with some of the creative ways that we are thinking of developing these clinically. The ambition here is not just to get a collection of interesting targets and start the screening.
It is really to how to develop a repeatable approach for progressing from genetic insight, understanding the mechanism, selecting an ASO, getting some translational proof, and then using our ability to run very efficient development programs to provide the clinical evidence that we need to move these programs forward. I think elsunersen demonstrates that we can actually move an antisense oligo program forward. We can provide the packages and the evidence level required for approval, and we are close to that. These programs now create opportunities to test whether the next level of approach for our ASO development can be done to repeatedly do it, and to do it more rapidly, and to bear the fruit of that in much shorter order. That is the platform we are building, and we will say more as we learn. I will just close now, wrap up. This is another snapshot of our current pipeline.
Let me just close with a bit of a larger picture. Across essential tremor, developmental and epileptic encephalopathies, pain, and our RNA platform, Praxis Precision Medicines is pursuing the same scientific idea: identify the mechanism that makes a neuronal circuit dysfunctional, then build a medicine that addresses it as precisely as we possibly can with the knowledge that we have got. We have late-stage clinical evidence, a series of near-term development milestones, and platforms that can sustain future programs. The opportunity here is to turn deep knowledge of neuronal physiology and genetics together with our ruthless execution of clinical trials, and to make a measurable difference in patients' lives, and as Marcio says, to do it again and again and again. With that, I will thank you for bearing with me.
I will invite Marcio to the stage to host the Q&A session and the other speakers to come up to the stage as well.
People have their hands up already.
I cannot see them with the lights.
I know. It is a little blinding, the lights.
Yeah.
It is hard to pick, so I am probably going to ask someone else that can see everyone, maybe Tim or John, to help us pass the microphone. Since I see you, Ritu, why don't you start? I will give you a microphone, though.
Thanks. Thanks, Marcio. Thanks, everyone. Ritu Baral, TD Cowen. I want to ask, we will go through chronologically for the day, but the very first question, as you presented the Ulixa market dynamics, how do you see that first early stage of launch going? Now, if we looked at those curves, you expect a high peak sales, you expect the early launch to outperform average. But given the sensitivity around managing patients early, how do you see the overall launch curve, say, in the first 12 months versus first 24, leading to peak? Should we be more conservative out of the gates to have a better control over the drug experience and reputation?
Yeah, absolutely. I will start and then hand over to Erik, John, or Megan, or all of them. I think it would be appropriate in a market that has been dormant to be a little bit more conservative when you are thinking about the first year. And for many reasons, right? We have been doing a lot of work recently, as you know, but there is no other. The same reason why it is so hard for all of you to forecast these markets at the beginning is a little bit less difficult for us, but it is still difficult to understand the beginning of the curve. If you were to take at face value the initial interest, right? We did not update the numbers on patients that we have in the database intentionally today, right? So I think we are trying to make sure as well people just don't put a straight line out there.
We know we are talking about hundreds of thousands of patients that we have direct access to. But there is a certain energy to activate, and I don't think it would be responsible for us to just say, "Put a straight line out there." Now, when you pass the original, the initial month, two months, three months, six, 12, then there is no stopping this launch. And I think that that is what Megan, and I will hand over to her, tried to say with that slides, right? We are not saying, "Oh, keep the expectations as low as possible." By no means, right? Wouldn't be me here if that was the case. What I am saying is, on a market with nine, seven, two, we are talking millions, right? So does it matter which number that is? It is pretty easy to get to very high numbers, right?
On a market that, as you heard so eloquently from our speakers here, the unmet need is basically prescribed to almost everyone. Unpromptedly, physicians told us 36%, 40%, 50% of their patients. We need to learn on the first few months of the launch, and I think that's what we're trying to say.
Yeah, maybe just building on what Marcio shared. The emphasis around our Commercial Data Foundation, Ritu, is also part of our ability to understand exactly how everything is going along the patient and the prescription pull-through journey. While I think, as Marcio said, kind of that cautious conservatism, we're still going to be pushing and we're still going to know exactly how this launch is going every single day. But I think maybe, as Erik and John had shared as well, we do know everyone's first experience matters. So that's where we want to have that kind of controlled. We're naturally all control freaks. So you want to make sure you can control for that experience.
But we feel really excited about both the infrastructure we're building as well as the Hub of the Future model, and solving for a lot of the things like Dr. Kremens said around the smoothing for the payments. That will be part of the service that we can educate on. So, we feel like we've solved and sort of solved for a lot of those barriers that typically do hold the launches back while recognizing this dynamic at the beginning.
A very specific follow-up to that. The commercial team mentioned at one point, as you looked at that sort of patient flow, a third of patients might need extra support. I believe that was on a slide for sort of the throughput. Can you elaborate on that a little bit?
Yeah.
Erik, you want to take that?
Yeah. So the extra support, she is talking about titration?
Yes.
Yeah. Okay. Just making sure that we are all on the same page there. Yeah, so from a titration support, that is the most important time for them coming on to therapy. So we do have, as part of the go-to-market plan, a pretty robust compliance and persistency touchpoint plan that we will be checking in with the patients, making sure that they understand exactly what to expect out of the gate as they get into the first step-up in titration, knowing what is coming, making sure that they are ready to have that step-up. So we will be high touch in that first titration period and then getting them into maintenance. Not every patient is going to need that. So this is designed, as Megan has talked about, that we understand exactly in the data and in our customer touchpoints who needs what, and the model will support the varying levels of support.
Yeah. It is also the reason why we built in that dynamic targeting capacity. So we will know if we have not touched that HCP, once we get an indicator that an RX was written, we will be within the office in 24-48 hours. We provide the education to them before that script is sent. Then the patient would receive that education from the office, because many times they do not pick up for their SP. They will certainly pick up for their office. So we feel very confident about that.
Hi. Thanks for the presentation. Joon Lee from UBS. ASMs are considered a protected class for Medicare Part D. Do the Medicaid and commercial payers consider it as such as well, or at least give it greater consideration? What does that mean for potential combination with two or more branded ASMs? The other question for, based on the last part, for a lot of the ASOs for specific DEEs that you mentioned in the last part, what is the regulatory strategy? Wasn't the whole point of EMERALD as a basket trial due to the rarity of individual DEEs? Will you be relying on open-label single-arm trials like elsunersen or something else? Thank you.
Maybe even start with the last part there. You might have noticed, like when you look into the Praxis portfolio evolve, Joon, the ASO portfolio is probably a little bit slower. Right? We've been talking about this for a while. Part of that is the regulatory framework is changing when you're talking about ASOs. It's changing a fair bit, right? So the conversations we have with the agency or Praxis, it's not entirely clear, like how, I'm going to call flexible. I don't necessarily think the word is flexible here, but how broad the approach on certain steps that are being removed are going to be. We're very encouraged with the idea that not everything that was done before for small populations are necessary right now. We've been, I think Steve very properly avoided talking about our regulatory strategy today.
We are a lot more certain on what we believe is going to accelerate all those drugs today. Probably not to the point of combining multiple indications yet on the same program, but certainly on the point of the level of evidence matching the current statutory and new guidance versus matching old guidance, if you know what I mean, right? I think there is a lot of talk about how do we accelerate life-transforming medicines to small populations. There's been a very little action in relation to that. I attribute most of that to companies, not to the actual, to the agency. I think we need to just be more adventurous, I'm going to say, and really go and work with the FDA and with the HHS and others on that endeavor, and we're very willing to do that.
On that regard, I think we're going to see a lot more. On your question about how CMS is going to see it and whether or not, we think this is going to be incredibly straightforward, right? Looking through all the analogs, looking through all these populations, are they all protected for the smaller indications? So combination, there is no expectation whatsoever that's going to be an issue here. As you heard from the experts today, it is not an issue as we speak. I think sometimes people try to make an issue out of market access, versus actually looking to the evidence for market access, particularly in fragile populations that are disabled, right? Most of these kids are disabled. So we think it's going to be fairly straightforward there.
Hi, Marcio and team. Thanks so much for having us for a great day here. Tessa Romero from JPMorgan. I wanted to ask a little bit about how you think about what an ideal label looks like in your eyes for both ulixacaltamide and relutrigine, and what can you tell us about how that compares to what seems to be important to the agency based on what you know today, and are there any areas of pushback?
No, fantastic question. As we are entering, or are in the middle of conversations like this. I'll start with ulixacaltamide. I think, one, because we're, as you saw in our disclosure, our Form 10-Q earlier this week, it feels more advanced, that conversation with the FDA at this point in time. I'll remove the controversial parts, or non-controversial parts out of that. So indication is, I don't actually believe it was even ever discussed, because it's for the treatment of essential tremor in adults. There is no subgroup, as Steve showed, that have a difference. Normally, we start getting to this nitpicking on label when you have a subgroup that behaves very differently than other. That's not the case here.
There is real no important restrictions in terms of special populations at this point in time that we are aware of or any of the conversations we had with the FDA. There's very little evidence that any of the metabolic parts or section, specifically PK and PD interactions here exist that would impact safety or efficacy on the drug. So everything that we tend to be, as people write those labels and trying to inform physicians, the real points of understanding and discussion has been titration. And mostly because of, not because of actually a lot of the questions we get from all of you, but because of a joint, I would dare to say, a joint understanding from us and the agency that this drug works very fast, and the titration might, the discontinuation might have been a byproduct of how fast it worked for some patients.
In a very simplistic way. What can we do to keep the 70% or so of patients that respond really well, responding really well and very fast, and inform clinicians, that is what prescribing information is for, inform clinicians on some alternatives they might have? One we proposed from the very beginning after discussion with them back in December last year was to borrow some data from our phase II study from PRAX-944-222, or Essential1, as you know, and use that data together with all the data we have on PRAX-944-321, that is Essential3, to combine and to come up with a strategy. That strategy is actually very simple. It is just keeping patients a little bit longer on 20 mg to have the benefit.
Now, clinicians tell us they are going to do all sorts of things to do that. I am a little disappointed that question did not come up today. I would love to have heard the answers. That is maybe the area that I would say we took the most developing. Take the worst-case scenario there, and it is still really positive for us, right? The worst-case scenario is physicians are going to have to figure it out themselves. That is how I look into the worst-case scenario. The best-case scenario is that we figure out together by some indication in the label. When you go to relutrigine, it is slightly different. I will say it is slightly different. You all probably read our disclosures earlier this week. We do not have much visibility on that yet from the agency.
Would not be possible for me to comment on areas that are there, and maybe I didn't address, and then someone is going to create a conspiracy theory that I didn't talk about Section 14. Before that happens, let me address Section 14 for ulixacaltamide. I think we expect to be very robust, the description of the studies on the clinical section of the label for ulixacaltamide. But it is incredibly difficult for relutrigine right now because we are not to the point that we advanced the conversations enough, unfortunately, may I say, to be able to give you that.
Thank you, everyone, for that wonderful presentation. Great session. A couple questions from me. Yatin Suneja from Guggenheim. First question is on the new data that you shared today on ulixacaltamide, the long-term durability data. I mean, it is remarkable to see the doubling of effect over two years. The question is that just a snapshot of the data? Will you update that? Now that you have seen durability in these patients, how should we think about, or what are your assumptions for duration of treatment? So that is one. Maybe a second question is around the DEA scheduling. I mean, does that limit your ability to sample, and what does it mean for prescribers? Thank you.
Megan can describe the actual collection of the data and Steve can talk about the implications.
Yes. So certainly, it is a snapshot, as Steve had outlined. Much to your questions, we amended and had to update the system, so we just started that in November. But we were certainly thrilled to sort of see the analytical of matching what we were hearing anecdotally from these patients in the study. I mean, I have study team members tell me often after investigators have the calls just how well these patients are doing. So it's great to have the data match what we were hearing. From a commercial perspective, we do expect a durable, persistent effect. I think what we're trying to do is just manage to make sure we get as many patients up and through and dosing in maintenance.
The other thing I like to share, from a mechanism perspective, the beauty of this molecule is when you remove it, you lose the effect. So there's almost a self-governing mechanism built in that even if some patients may say, "You know what, Dr. Andrade, I'm not sure," and then they stop, the tremor's going to come back. So that also kind of helps keep that persistence, and as Steve outlined, the durability that we saw in the study too confirms that from an analytical perspective. So we certainly will continue through, patients have to re-consent with the new amendment, and the study visits are a little bit further apart in the OLE, so we'll continue to collect that data. But for us, it was a great confirmation of what we already knew from the study.
I mean, just mechanically to clarify one point Megan just made. So we had no assessment for efficacy on study three, that we call the long-term extension. So we amended a few weeks back. The very first assessment was like two and a half weeks ago, maybe less than that.
Not even. November 1.
From that point to yesterday, 4:00 P.M., there were 68 patients that were assessed. This is not a subgroup. This is not like we just picked out of the hats. This is not the 68 that exists. If we gave us a few more weeks, would be hundreds. It just so happens that in about 10 days or so, 68 visits existed, and we are able to show the data to you all today. It is an ongoing process, right. It is also like in the chart we showed are the baseline week 12 and week 95 of those patients, right. So that is not that we are mixing like another cohort. So you can really have a good idea of the entire sample we have today on just how it is incredible, right. It is remarkable. It is better than any of us expected to be on this patient.
I think that is how it should be seen. If this does not put to bed once and for all the conversation about whether or not there is a loss of effects on this drug, then maybe you should change professions. But this is pretty darn clear, in other words. On the scheduling or the potential scheduling, being clear that we are not sure that this drug will be scheduled. I think we said, and what I mean scheduling, I mean DEA scheduled, or what we said earlier this week and throughout the program, is that there is euphoria, there is dizziness, there was brain fog presented during the development program, areas that, of course, we always have to observe. And we always have to ask the question whether or not this can lead to abuse, and the agency takes this incredibly seriously.
HHS takes this seriously, the DEA, and all of us as interested members of the public should take it seriously as well. We did a full assessment. People know this as 8FA. I think most of you know the eight factors. In our view, it actually does not qualify as needing a schedule, but it is not our decision, right. And we submitted that to the FDA, and they assessed. They did confirm to us that the assessment is complete, but we are not knowledgeable yet about what that. We are taking the position that based on historical evidence, that it will be scheduled. And now we have been operating under that assumption from the get-go. And maybe I will ask Erik and speak a little bit about the lack of impact in our launch versus the impact in our launch for that.
Yeah, sure. Thanks, Marcio. We have been planning for this all along, for this potential. There are a couple things. One, in the neuro space, there are multiple scheduled drugs, so this will not be anything new or unusual for the stakeholders that we will be educating on this side of things. Then, the biggest impact, as you mentioned, is on samples, retail pharmacy, two items that were not ever part of our plan anyway. We were not planning to sample. As I mentioned earlier, we are going to be in the specialty pharmacy world. So the impact out of the gate then is less from that perspective. It really gets into just a couple things around timing perspective, other than the obvious impact of the 90 days for DEA to do their work.
We expect payers will wait until that is complete before they start the P&T process, so it kind of just moves everything out. We were counting on scripts being good for a year in a scheduled scenario that it is six months versus a year. So, still a meaningful script that is going to come in there, but it does affect the number of touchpoints in that first year of coming onto therapy. But other than that, there is very little effect into how we plan things. The last point I would make is, Megan mentioned earlier on the Commercial Data Foundation, we have planned to remove friction at every point along the pathway, and this just makes the CDF that much more, and Hub of the Future that much more important.
Jay Olson, Oppenheimer. Thank you all for hosting this comprehensive event. One of the initial strategies we have seen for the successful launch of innovative new therapies like ulixacaltamide for ET, where you are pioneering a new treatment paradigm, is a physician referral service where you could help patients with ET or suspected ET find physicians who are trained in the diagnosis and treatment of ET to ensure a fair trial with an optimized probability of successful treatment experience. So we are wondering if a physician referral service is something you would consider so patients can more easily find and access excellent physicians like Dr. Ondo and Dr. Kremens. Thank you.
John, want to speak a little bit about the overall coordination in the fields?
Yeah. So, that would absolutely be in the plan. As a part of the earlier presentation, you kind of saw that where we have the target on the neurologists and their networks and their centers. Dr. Kremens and Dr. Ondo both spoke to this, they will follow the lead of the folks that are out front that are starting with the medication. But we do have a strategy into PCP to help with that referral pattern. Absolutely right. So, the good thing is we're not going to wait. We're going to launch with that strategy and feed into those centers as best as we can through coordination, and have had a lot of experience on success with that in the past. So that's absolutely part of the plan. Yeah.
Hi, Kevin Strang from Goldman Sachs. Thanks for taking the question. I wanted to ask one on relutrigine for the SCN2A, SCN8A population. You talked about the diagnosed population versus the identified patients. Can you talk about how you might work to sort of bridge that gap and maybe some of the barriers there? Also just on the launch itself, how should we expect sort of the pace of uptake in that population, especially among the identified patients? Thanks.
Yeah. Megan, want to take that?
Yeah, maybe on the first point from a patient population, certainly the 1,900 on the diagnosed and known, I think as John and Erik had shared, because of the account profiling we have already done, we are already north of that. That was, again, part of that deliberate choice to invest and build in the field early so that we had the account profiling done. I do not think we will give any more specifics other than that, but we have already broken into that middle column from the work to date. I think the dynamics and sort of the uptake is probably not dissimilar to Ulixa, but for different reasons. I think I mentioned in my opening, while we will have the first approved drug for SCN2A and SCN8A, we are changing the treatment paradigm. Caregivers, moms and dads have gone through this journey.
It has been a hard journey, one of fear and concern and failure, trial and failure. This shift that we will be bringing to the community may take some time, but we are certainly encouraged. I mean, you heard from Dr. Smith and Segal. They see the opportunity for their patients. One of the things that Erik had mentioned, which we will double down on, is bringing that Hub of the Future and direct patient support to both the caregiver and the offices so that we can help these children get on treatment as quick as possible. This is just game-changing efficacy and life-saving for them. But we are also recognizing it is new. They have never had a branded drug specifically for them.
Over here. Doug Tsao from H.C. Wainwright. Couple questions. First, I wanted to start with relutrigine because I think broadly when we think about the market opportunity, when we think of DEEs, we generally think of a pediatric population, although there are a fair number of adolescents and even young adults and sometimes even older. How significant could that patient population be for you? I mean, because you do have weight-based dosing, so for some of them, those could be fairly high-value patients. Just how are you thinking about accessing that population? Then I have a follow-up on Ulixa.
In a sense, we are already done that. If you look into the slides, Steve presented with the mean age, it kind of answers your question that there is a fair bit of, I am going to call older patients on EMERALD right now. When you do the profiling, there is a very large number of patients there. I think many times in the past, we talked about SCN2A and SCN8A and KCNQ2, these like very high early mortality DEEs, and most people equate, rightly so, to pediatric conditions. But there is a number of them that, while incredibly important from a seizure burden perspective, mortality is not that high, or early mortality. Mortality is 100% to all of us. It is early for these patients. It is more like Dravet that is kind of a little bit later in life or even later than that. You are correct.
We intend to price this as weight-based and to the initial targets population. We are focusing really on the clinical benefits for these patients. It so happened that, yes, they would contribute a little bit disproportionately to the overall revenue as well, but the focus is the clinical benefit for the patients.
Yeah. Okay, I'm back. I'm sorry. Just wanted to add a question on pricing, because you provided some analogs that you provided today, and those are generally markets with somewhat smaller patient populations. Not super rare, but if we think about tardive dyskinesia, not as prevalent as what we see for essential tremor. Some of those categories are a little bit. On the flip side, some of those have competitive pressures. But in talking to payers in checks, some of them sort of talk about the budget impact, just given the fact this could be a very large category all of a sudden. I'm just curious how you're thinking about ensuring access to the broadest population versus sort of having maybe a little more value per patient, more severe patients, but perhaps a slightly smaller target.
Yeah. We did very extensive testing on this. I'm going to start with that. I think we should do an invert panel one day and ask why payers are so profitable if they're struggling so much with price. We can take that in another day. But very extensive. One thing we are doing, and we talk a lot about the Hub of the Future, but we actually haven't talked about what that is. One of the key elements of that is alignments of incentives, right? I hope we are all capitalists at heart here in this audience, because that's what made this country great. Today, referral of prescriptions to payer networks does not follow the best path. Most of that exists because technology was not available to allow for that.
Without telling you a lot more than that, I'm going to say that we are aligning that incentive structure throughout, number one. Two, anyone who believes in elasticity of price of drugs in the U.S. should go back and take a look at the numbers. There is no elasticity. This idea that drugs are times population, it's just so wrong that it's not even worth debating. There's actually a very recent report that beautifully illustrates that, and more than happy to share with all of you. That's not how people see it. Maybe the last one is, between now and 2029 or 2030, there's going to be over $100 billion in LOE that's going to continue to fuel innovation in this field, and I think we're all going to be fine.
The most important thing for all of us, for physicians in the audience, for patients outside or inside this room, for us as drug developers, for you as actually allowing us to develop drugs, is that we continue to do this. One of the sine qua non conditions for that is capital to flow properly. I believe the system, despite not being perfect, is actually pretty good right now for innovation for patients.
Hey, thanks for doing this event today. It was really great, especially the DEE panel. The guy who hosted that really had some-
10 out of 10.
10 out of 10.
On Ulixa, could you characterize your thoughts on the number and composition of NDCs you are planning to have at launch? Is there a thought around a blister pack? Is it just going to be a 20 mg, 40 mg, 60 mg dosages? Thanks.
Yep. We have three options right now. The standard titration would be the 20mg, 40mg, 60mg for a blister. We will also have a straight 20 blister pack, and then the 60s in bottles. Certainly as Marcio outlined a few minutes ago, the expectation that there could be some flexibility in the label for a slower titration. That is what the 20 blister will allow.
Thank you for the great presentation, and happy birthday, Tim. Kambiz Yazdi, U.S. Bancorp | BTIG. A question for Dr. Petrou regarding the idea that T-type calcium channel inhibition is potentially the GLP-1 moment for the brain. Development of the GLP-1 class was quite iterative, of course. Steve, in your view, what were the most important developments in the T-type calcium class to get to ulixacaltamide today, and what are the most important steps to broaden the class for the future?
Yeah, I mean, I think we already talked about that in terms of some of the more proximal areas around ulixacaltamide, the RLS and the PD. I think you can already see that anything related to behavior that emanates through the thalamic process is fair game in this space. These calcium channels, every action potential that results in the body always causes the release of calcium. So it is the final step of any neuronal network process. We have never really tested in any systematic way with great drugs what that can do pharmacologically for people. So I think we are just starting to get our thinking caps on even more and more now in this space. There are obvious choices because there is data that is coming out from literature, and our own thinking is colliding in those three areas.
The world is our oyster, and we do not know what happens when you have a bias for one of the subunits, like 3.3 versus 3.1, what might happen, how you might tackle different. Ulixacaltamide, people have been talking about it in pain, people have been talking about it in generalized epilepsy because ethosuximide is one of its elements. I mean, there is great data showing the effects of ulixacaltamide in absence epilepsy models. So it is mind-blowing when you think of the disparate neurological areas that are impacted by ulixacaltamide, and therefore, what does this class do when you have a bit of mastery over the modulation of it? So that is why I think it is green field for, if you know, it has not really been tackled by the pharmacological sector to date at any level. This, I think, ulixacaltamide's approval is that foundational event.
Kambiz, you asked a question, I will ask Steve to comment. What is the difference? There were other attempts here. We tend to be overly simplistic on this because we do not want to keep talking about failed attempts. But there are, sometimes we are so convinced that what we have done for other molecules is just going to work for a given molecule, like state dependence. Oh, because state dependence is important in certain channels, chloride channels, sodium channels. It must be important on calcium, T-type calcium channels. We believe it is unimportant, actually quite the opposite. So that is one of the difference. The other two molecules that have been tested a little bit more extensively here are highly state-dependent. We are not trying to make the oscillation start to overlap like waves less.
We are trying to remove some of these channels from the available pool
Permanently
permanently. That requires that both states be activated. We are trying to get enough drug in the brain, and as you know, the classical example is suvecaltamide. There is just not enough drug in the brain, period. We are trying to get a drug in the brain that you can control the concentration, not through the M2 metabolites, as that drug does, for example. So I think these overly simplistic views of the world are actually not very helpful in biology. There is the basic interaction with the channel or with any other protein for that matter, and then there is everything else that happens when you give it to a human. That is the mastery part that Steve was talking about, if I
Yeah, I think you touched on all the key points there, Marcio. We even know with the sodium channel, the profile of action, and it's the manner in which you interact with your target matters in human biology. We are seeing that with relutrigine. We are seeing that more and more. And yeah, it was beautifully exemplified when we look at the CaV3 T-type calcium channel modulation products that are out there. And then the drug-like properties, that was something I called out. We want to control that. And our KOLs talked about that. Easy to use. Does it have the right metabolic profile? Well, it's not easy to use if the metabolite is the active aspect of the drug. So these are all the properties you need to think to have the right molecule at the right space at the right time, and modulating that target.
These biological targets are really complicated, and I think we black box them too much. Like, it's a sodium channel thing. You gum it up, and it's a black box, and you just got to block it, and that's all you got to do. It's a lot more subtle than that because biology is more subtle. And I think if we have a bunch of molecules that allow us to explore that, we are going to learn a lot more, and we will see these sort of weird differentiations. Well, that was a T-type thing, and it failed, and that worked. It's not necessarily that could be the reality, and it probably is the reality of the situation that we are in. If they could stop the metabolism, if they could get more in the brain, these problems might go away.
But you can't use that molecule and get more in the brain because you will change its properties as soon as you fix that profile.
There's a super interesting thing with T-type calcium channel, T-type calcium channel inhibitors, is that there is a signature when you give to people during non-REM sleep. Steve talked about this today. It's pathognomonic if you want to think about that as pathological, and it's just a signature if you want to think about that as not. There is a reduction in power in sigma bands during non-REM sleep periods. I believe no one ever asked why the other drugs don't have that signature. Maybe because they're not in the brain. Maybe they're not in the brain, it's the concentrations. Maybe they're not inhibiting the channel in a way that is selective enough, things like that.
Absence of evidence that is definitive should be a big doubt in drug development, and it looks like caltamides, and of course, 50, 51, and others that we discussed today have that signature, because we know it interacts, periods. That is being demonstrated very clearly across the years, around the years. We have been avoiding the back of the room, so there are people in the back. Yes.
Hi, Marcio and team. This is Orpheus on from Ben Burnett from Wells Fargo. Thank you for hosting us.
Of course.
On Ulixa, it was helpful to see the sensitivity analysis you showed us. Just to clarify, was it an exhaustive list, or did the FDA also require additional sensitivity analysis?
Yeah.
Thank you for showing us the OLE data through 18 months. Can you also talk to seizure freedom throughout that period as well? Thank you.
Yeah, absolutely. So that's exhaustive list. It sounds small just because you haven't seen a lot of other exhaustive lists out there, because to our knowledge, we're the only company that ever showed the analysis that being during an NDA review requested. They're actually obvious, and I think from the beginning we've been saying they're obvious. There's only so many ways monotonic missingness can be tested. There are esoteric ideas by people who are armchair statisticians, but people who actually do this for a living know that there's only so many ways to do it. So that's exhaustive. And of course, we're very happy that they're all positive, but it creates an absurdity that I want to close today. Dr. Fisher proposed the alpha level at 5%, and that's how we test drugs in the United States and everywhere else.
The idea that you not only test below 5%, but then that now you pressure test and they have to keep staying below 5%, it's probably a major misunderstanding of the central theorem of statistics. Enough said on that, and I think that we should close that chapter today. In terms of relutrigine, it's a very high number of patients that are seizure-free on this study. You're going to see the exact same charts as on the manuscripts that should be published very soon. We thought it was important to show not only how big the effect is. It sounds almost absurd, right, that you actually can get a population that is start with so many seizures and then throughout the 18 months, the vast majority of them have large periods, long periods of seizure freedom. Sometimes breakthrough seizures happens with these patients.
They have a genetic defect that creates that, but it's incredibly encouraging to see what's happening. And even more so, and I think always brings true tears to my eyes, is when you get the narrative from these families on what they are able to do because of the seizure freedom. And I couldn't agree more with what Erik and Doug mentioned earlier today. The impact of reducing seizures in this patient population is incredible. You'll see more pretty soon about that.
I'll be quick here. Just a quick one in terms of, I'm thinking about the launch and a lot of good questions on the Ulixa kind of ramp up here. I was just wondering, when we look at the efficacy, we heard today that even one point can matter for a patient, but we also see a lot of patients that are, whether they're considered super responders or not, but like, 10- 12 points on the ADL. Is there something about those patients where we know how to target those specific ones? Is it something that, like, look, it depends on severity or something like this? If that's the case, are they also the ones that might respond better to propranolol or this new mechanism, they have nothing to do with each other?
Just trying to see if there's any low-hanging fruit out there for that.
You want to start, Steve?
Oh, you can.
All right. There is one answer there, one question that we cannot answer, because we haven't really got patients like naive to propranolol, naive to this drug, and then run both of them. But I think what we heard today was not that it can be one, you added the words there, is that is meaningful. I want to make sure that I correct the records. When you're looking to 10 points, 20 points in some of those patients, we see as points, but they see as life-changing for all of this. Is there a predictor? Not one we can find. The proportion of patients who were on propranolol, on those super responders, as we call, are actually very similar to the ones that were lower, if we can call responders. It does not look like that there is a predictor here.
One point we made in Seoul, actually, when we were presenting at the International Parkinson and Movement Disorder Society meeting last month, I guess, a month and a half ago. Time is weird these days. For any reason that we still don't know, when you get a large cohorts of patients who have been treated with propranolol for a long time, as those patients were, they're indistinguishable from patients who were never treated. In other words, maybe propranolol is not doing a lot for these patients after a while. As Dr. Evans mentioned today, it's the alternative we have. So we're keeping these patients for on the long run. Both ourselves and the FDA ran quite extensive analysis on trying to understand predictors, and we're very happy to hear, number one, that our analysis matched, which is always good.
I think we're trying to figure out if that is something that we could work together and figure out. But it might be because it's essential. Fundamentally, we don't know why it starts. That is what the words actually means, if I'm not mistaken. And there are many ways they end up there. To end up with a study with 400-plus patients that no subgroup is actually inferior to drug, at least nominally, it's actually nothing short of a miracle. I read every single edition of the New England Journal of Medicine, and there's not a lot of those studies out there, and that we all call success. So I think we should feel incredibly happy about what we are seeing here with E3. The back. I used to be a back kid, so I got to
Hi. Mike Obudai from B. Riley Securities on behalf of Madison El-Saadi. So just for the EMERALD study, what percent of patients do you expect to be SCN2A or eight, just so we can understand what a top five etiologies could be? And again, it's such a broad study, so I have an all-comers study. How many percent of patients do you already kind of expect to not respond to relutrigine? Because again, it's so broad.
Yeah.
Also, again, there might be patients in there who experience 100 seizures a day versus four seizures a day. How do you manage those outliers? How many outliers are you expecting? Thank you.
Yeah. Steve can maybe start with the ones we are expecting to respond, because it was mostly of his talk, then I will talk about characteristics.
You mean in terms of genotypes?
Yeah, or etiology in general.
Yeah. I mean, look, it is meant to be genotype agnostic. If you are having a lot of activity, you are going to be a candidate for being blocked here, meaning having efficacy with this drug. Maybe things like KCNQ2 might have more pharmacosensitivity because they share a compartment with 2A, they share a clinical presentation, so there is a possibility there that we get some more overlap in terms of it. Beyond that, we do not see. There are some of the patients in this thing that do not have a clear genetic ascertainment. We think the clinical presentation is going to drive what we see pharmacologically here. In this case, that is the really hypothesis that we are testing here. We are not seeing why a particular subgroup should be different if they have seizures, and we have got seizure counts. That is an inclusion criteria, obviously, here, to have the right seizure counts. We are going to expect efficacy.
In terms of the number of SCN2A and SCN8A
Yeah. I can comment a little bit on that. Both intentionally and unintentionally, the number is, I would say, relatively small, just because the study is about 200 patients, right? Not as small as small numerically. One of them is, we were told by the agency, "Well, it works in SCN2A and SCN8A, so do not bring us a study with 75% of SCN2A and SCN8A. That is not going to cut it." That was a little bit more. There is another practical aspect here. When you talk about SCN2A and 8A, DEE, early onset, these patients cannot stay for 12 or 16 weeks without changing regimen. We have not talked much about this before, but we had several patients dying during screening, right?
I keep hearing this Dravet BS coming out, and I have a lot of respect for Dravet and their kids and so on, but this is not Dravet. These patients die a lot. You just cannot do it. They could not. The majority of the SCN2A and SCN8A patients, they just could not be on this study. There are a lot of other etiologies that were sensitive, as you heard both Doug and Erik talking today, that are sensitive to sodium channel, first generation, second generation, that they just could not stay on them. That seems to be a high enrichment for patients that responded but could not stay on for tolerability reasons, for immunological reasons, or others, which obviously increase the confidence. I think what you heard as well for Erik, who has both on his side, right? Both studies, Broad Z, you know which one.
The other is, there's a very high confidence on this study as well by what has been seen before. I know the perennial question is Dravet, right? It's like, "What happened? How many" There were like 10 patients with Dravet in this study. It's completely irrelevant for It was never our intent. We believe Dravet to be a treatable condition today, and therefore the residual unmet need is basically nothing. Not surprised there's not a lot of patients. That is 10% of the Dravet population, by the way, that are gain of function, and those actually have no alternative today. So for them, might actually be quite interesting. But outside of that, it was a very diverse pharmacosensitive and sensitive to the mechanism population. Soon enough, hopefully you're all going to be celebrating how we are helping these patients.
I thank you for taking my question and hosting today's event. I'm Ami Fadia from Needham. My question is about relutrigine, and Steve's discussion about its unique mechanistic rationale was quite interesting. Based on that, do you believe that the efficacy is likely to vary much across different DEE subtypes? You noted 4% market share could drive $5 billion in sales. Where in your expected range of outcomes does 4% lie? It seems fairly conservative, just given what we've seen with the longer duration of efficacy in 2A/8A. So I'd be curious what you would need to see in the upcoming data readout, maybe to revisit that number.
Yeah. I think we heard from the opinion leaders, right? StatSig is the bar. I swear to God, we did not brief them. We not even had a call to brief them. That's the bar. I think that 3% or 4% was illustrative.
Yeah.
It so happens to match most of your models. So, that is a little coincidence there. But in a sense, it's an indirect way, maybe provocative way, to ask yourselves, do you really think 300,000 patient population in the U.S. that is still having life-threatening seizures every single day with a new mechanism that reduce that will only be single-digit percent market share? So, I'll let you all respond or answer that question. I think it's a pretty obvious question and answer, but I'll let you revise your models and increase the PTs. No more? One more?
Hi. Thanks for hosting the event and taking my question. David Hoang with Deutsche Bank. I wanted to ask about the ulixacaltamide launch. As we think about the different sites of practices that will be prescribing the drug, we have, I think, MDS clinics, general neuros, and primary care all in there. Also thinking about some of the peak sales numbers you put out here, how important are each of those prescribing segments to the overall market opportunity and peak sales? How should we think about maybe the rate of prescribing among the different segments?
Erik and John, you want to talk a little bit about that?
Yeah. Short answer is all three are important. We see obviously the higher percent of patients are being treated by the movement disorder specialists and the neuros. The number of PCPs that see more than one or more than a handful of essential tremor patients is meaningful as well. That is why our target list does include all three, and all three are a focus out of the gate for us. We have tiered them based off of potential that goes across influence, number of patients, et cetera. That is the work that John's team is starting to pursue now and we are working on over the next few months.
Yep. We base that based on the claims data that currently exists, to Erik's point. We score them. The most important thing, I think, is that we validate that during the profiling period, right? We have this period of time before FDA approval where we can actually go into the offices and ask questions, or even the number of patients that may exist in the office. Then we can re-tier at that point. That gives us a real opportunity to have precision when we go to launch. It is a pretty good thing that we have.
In rough proportions, David, to you, I think it's a well-known fact that the movement disorder specialty is pretty small. I think that maybe with more and more companies developing drugs and more things, there are going to be more fellows and more specialists and more people interested on that. But by the fact that it's small, we end up seeing really a limited number of patients. When you look into raw numbers, it's about 3%-5% of the total prescription base we expect to come from MDS. Then the remaining of that, the vast majority from general neurologists. As you might have heard this morning, there is a very good relationship there already established, right? It's not other areas of knowledge or medicine that it's adversarial. That's quite the opposite here.
I think there is a quite nice relationship established when they know who to call in the region if they have a question. Throughout the years, we do expect that this specialty is going to grow and it's going to migrate a little bit more of that. Years two and three of the launch, as we think, PCPs start playing a bigger role here.
I was going to say getting beyond the 2 million that are actively seeking treatment and getting above and pushing into that 9 million, that's when the primary care physicians become much more important.
Good. Is that it?
Great.
All right. I guess we are wrapping it up. I really appreciate everyone being here. I hope we accomplish, I guess hope's not a strategy, so I'm sure we accomplished the two objectives that we had for the day. Appreciate everyone spending a lot of time. This was a very long event, so I know you have other things to do with your day as well and spending time with us. Our commitment to have a really state-of-the-art, the gold standard was banned many years ago, so I prefer not to use gold standard, but really to have the best possible launch for both of these populations. It's a guarantee, it's not a wish that we're going to have. But also continue to expand. When you're talking about being the number one CNS company in the next decades, it is not a pipe dream.
I think people love throwing 2035, 2040 visions out there that are not founded on a strong foundation. But as you've seen today, it is very clear that that's the discussion we're going to have for the ones of us that love this business and still going to be in this room in a decade or so. So thanks for coming. Really appreciate it. Looking forward to interacting. I think we have reception, drinks, so please stick around if you can, and we can have more informal conversations as well. Thank you.